Complimenti.....Sei entrato nel piu' completo Portale sulle Medicine Alternative, Biologico  Naturali e Spirituali - la Guida alla Salute Naturale - Leggi, Studia, Pratica e starai in Perfetta  Salute, senza Farmaci ne' Vaccini


GUIDA  alla  SALUTE con la Natura

"Medicina Alternativa"   per  CORPO  e   SPIRITO
"
Alternative Medicine"
  for  BODY  and SPIRIT
 

 
 


AUTISM
O 
(Référes - Bibliografia )
Relazione-Dossier del dott. M. Montinari su Autismo dai Vaccini
Sindrome della permeabilita' intestinale ed autismo
Il Thimerosal dei vaccini distrugge e/o altera la flora intestinale essendo una sostanza altamente tossica
Ecco il recente studio che ha coinvolto più di 17.000 bambini fino a 19 anni
Questo studio-indagine attualmente in corso è stato avviato dall’omeopata Andreas Bachmair.

La Verita' sullo studio del dott. Wakefield
PDF degli studi sui danni dei vaccini, dal 1926 al 2009
Terapia Naturale per l'Autismo (Gaps)
AUTISMO e malattie varie dai Vaccini - Studi Pubblicati - PDF
Vaccine-story-Peer-Review-1000

Bibliografia aggiuntiva:
http://treasoncast.com/2014/04/05/anti-vaccination-peer-reviewd-research-list/
http://edgytruth.com/2016/08/21/vaccine-quackery-bombshell-key-studies-cited-prove-vaccines-safe-funded-almost-entirely-vaccine-manufacturers/#
https://www.scribd.com/doc/220807175/127-Research-Papers-Supporting-the-Vaccine-Autism-Link
 

USA, Giugno 2013 - AUTISMO = 1 bambino autistico su 26, non come era nel 2010, 1 su 80 ...

Sindrome infiammatoria chiamata "Asia" scatenata dai vaccini !
ASIA_Sindrome infiammatoria-dai-vaccini-Riassunto.pdf
Tratto da:  http://www.assis.it/wp-content/uploads/2014/12/ASIARiassunto.pdf
... ed e' noto che... le infiammazioni sono foriere di qualsiasi tipo di sintomi, che i medici impreparati allopati chiamano erroneamente "malattie"....

 

In CINA dopo le campagne vaccinali esplode l'Autismo ! - Maggio 2016
http://yournewswire.com/autism-rates-explode-in-asia-after-introducing-western-vaccines/
VERISSIMO, ma non solo l'autismo....ma una innumerevole sequela di altre malattie....
Autismo e non solo dai Vaccini:

Continua da e in:   Autismo Refenze 2 + Autismo Refenze - 3 + Amish senza autismo perche' NON vaccinano
Ma ricordo che, molta importanza hanno anche i cibi assunti non adatti al gruppo sanguigno del soggetto autistico.

vedi QUI: http://autismovaccini.com/2012/05/01/statistiche-per-lautismo-a-confronto-probabile-1-ogni-29-anziche-1-ogni-88/
Metalli tossici dei vaccini = Autismo vedi: PDF -  dott. M. Proietti

http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/  

CLAMOROSO:
Nell'estate del 2014 lo scienziato Thompson del CDC annunciò che in un famoso articolo pubblicato su Pediatrics erano stati omessi molti dati relativi alla popolazione afro della città di Atlanta
.
Tale studio “provava la non correlazione” MMR- autismo
vedi: http://www.ncbi.nlm.nih.gov/pubmed/14754936

Con le nuove dichiarazioni dello scienziato Thompson (confessate davanti ad una commissione statale US), il dr. Hooker ha analizzato di nuovi i dati che dimostrano senza ombra di dubbio che vi era un rilevante aumento dei casi di autismo fra i maschi afroamericani della città di Atlanta.
Nel febbraio 2004 Thompson scriveva in una sua e.mail, CHE TROVATE QUI
http://www.naturalnews.com/images/CDC-Gerberding-Warning-Vaccines-Autism.jpg

Nota bene: Allora era presidente del CDC USA (Centro per la prevenzione e il controllo delle malattie) la dr.ssa Julie Gerberding.

“We’ve not yet met to discuss these matters…I will be presenting the summary of our results from the Metropolitan Atlanta Autism Case-Control Study and I will have to present  several problematic results relating to statistical associations between the receipt of MMR vaccine and autism.”
Thompson già metteva in guardia il CDC USA circa problematiche relative a forte correlazione fra MMR ed autismo.
Tutto fu insabbiato
L’allora presidente del CDC USA, ... è ORA dirigente della Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health,
Qui il link:
http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-appointment-dr-julie-gerberding-executive-vice-president


La prova della FRODE del CDC per le cause dei Vaccini nell'Autismo - CONFESSIONE di un alto dirigente CDC, davanti al Congresso US

IMPORTANTE:
PROPOSTA di LEGGE per  STUDIO negli  USA sullo STATO di SALUTE FRA BAMBINI VACCINATI e NON VACCINATI (di nessun vaccino)
Il DISEGNO di LEGGE n° 3069 a FIRMA della DEPUTATA MALONEY NON E' STATO APPROVATO per cui  E' RIMASTO sulla CARTA.... e NEPPURE DISCUSSO dal CONGRESSO....a dimostrazione che NON si vuole fare vere ricerche sui gravi DANNI dei VACCINI......Big Pharma ringrazia...

"Noi medici siamo plagiati, fin dall'inizio, dagli insegnamenti universitari che ci vengono propinati da un manipolo di "professori"
 che
hanno il solo interesse di lasciarci nell'ignoranza sulla vera origine delle malattie. Alcuni di noi, alla fine, raggiungono la consapevolezza e mettono in moto delle grosse energie che provocano reazioni positive nel Tutto."
 By  Dott.
Giuseppe De Pace (medico ortopedico ospedaliero)

Indagine della correlazione tra vaccinazione MMR e l’autismo in Danimarca
http://www.jpands.org/vol9no3/goldman.pdf
http://www.jpands.org/vol9no3/stott.pdf

Una ricerca indipendente della dottoressa Theresa Deisher sulla correlazione fra Vaccini ed autismo e non solo...:
http://www.vacciniinforma.it/?p=2314
Sintesi:
Ricordiamo la pubblicazione nell’anno 2014 dello studio del Dr Theresa Deisher. Questo continua a far parlare di sé . Cerchiamo di ricordare anche qualche fonte in merito.
Uno studio pubblicato
http://www.academicjournals.org/journal/JPHE/article-abstract/C98151247042
rivela una significativa correlazione tra il disturbo autistico (AD) e i vaccini MPR (morbillo, parotite e rosolia), quello per la varicella e quello per l’epatite-A.
Utilizzando l’analisi statistica e i dati forniti dai governi di Stati Uniti, Regno Unito, Danimarca e Australia occidentale, gli scienziati del Sound Choice Pharmaceutical Institute (SCPI) hanno trovato che l’aumento nella diffusione dell’autismo corrisponde all’introduzione di vaccini che utilizzano cellule umane fetali abortive e contaminanti retrovirali.
Ancora più allarmante quanto afferma la Dr Theresa Deisher, autrice dello studio, laureata in  Fisiologia Cellulare e Molecolare presso la Stanford University e  fondatrice dello SCPI: “I vaccini  contaminati da cellule umane fetali non solo sono associati con disturbo autistico in tutto il mondo, ma anche con un’epidemia di leucemia infantile e linfomi.”
Un nuovo studio quindi  – che arriva contemporaneamente  alle notizia che il CDC ha deliberatamente nascosto la prova del significativo aumento di autismo tra i bambini afro-americani che erano stati vaccinati prima di 36 mesi di età. – solleva seri interrogativi sulla sicurezza dei vaccini, in particolare per la presenza in essi di cellule umane fetali abortive. Ancora un nuovo studio di cui in Italia non avremo notizia dalla stampa ufficiale, un nuovo studio che sembra non interessare nessuno.
Da parte nostra crediamo che le scoperte dello studio dovrebbero produrre quantomeno un’inchiesta immediata da parte della FDA, se non un aperto divieto dell’uso di cellule umane fetali abortive come substrato per la produzione di vaccini.
La Dr. Theresa Deisher, un dottorato di ricerca in Fisiologia Cellulare e Molecolare presso la Stanford University: “E ‘possibile che questi frammenti contaminanti potrebbero essere incorporati nel genoma di un bambino e  perturbare la funzione del gene normale, portando a fenotipi autistici.”
Si può leggere lo studio completo QUI
La Dr. Theresa Deisher ha trascorso oltre 19 anni nel settore della biotecnologia con varie aziende come la Genentech, Repligen, Amgen e le sue scoperte hanno portato a sperimentazioni cliniche per patologie multiple.

I Tribunali anche USA, confermano tranquillamente che il vaccino MMR causa l'autismo. Austin (USA) - 27 Luglio 2013
Dopo decenni di appassionato dibattito, per i genitori che probabilmente hanno perso i ripetuti ricorsi richiesti dalle aziende farmaceutiche e governi, che i vaccini infatti causano l'autismo.
Per i genitori interessati alla ricerca della verità, vale la pena ricordare che le stesse persone che possiedono le aziende farmaceutiche di tutto il mondo possono anche possedere agenzie di stampa americane.
La Ricerca di informazioni prive di propaganda è stata fino ad ora molto difficile.
Ma Whiteout Press non è qui per sostenere o contrastare i vaccini. Siamo qui per portare i lettori la notizia che è il tema e’ in black-out, cover-up e censurato dalle autorita’Sanitarie e Governative.
Tratto da: http://www.whiteoutpress.com/timeless/courts-quietly-confirm-mmr-vaccine-causes-autism/

PREMESSA doverosa ed IMPORTANTE:
Qui troverete una raccolta di studi che confermano che il Mercurio
DANNEGGIA la salute di coloro che lo introducono nel proprio corpo - Pero' occorre ricordare, per coloro che non lo sanno, che il mercurio e' stato presente nelle amalgami dentali (per 50 anni circa) e sotto forma di Tiomersale o Thiomersal, e' stato introdotto volutamente per ben 50 anni nei vaccini di TUTTO il mondo generando gli stessi problemi ben descritti in questi studi - Il mercurio e' anche presente in certi cibi, specie nei grossi pesci.
Il mercurio e' stato eliminato dai vaccini, prima negli USA e successivamente negli altri stati del mondo, per lasciare che le case farmaceutiche esaurissero le loro
scorte di vaccini al mercurio....e cio' con il consenso degli stati (ministeri della sanita')....e SOLO DOPO che da tutto il mondo nei vari stati si sono levate le proteste di cittadini, medici, ricercatori, associazioni di malati.....

INOLTRE i Danni dei Vaccini non si limitano agli ingredienti pericolosi che essi contengono, ma anche ai virus, batteri, spore utilizzati per i
vaccini, anche se, come  raccontano, "inattivati", hanno caratteristiche di grave pericolosita' perche' sono sostanze ESTRANEE (i virus ed eccipienti) e microorganismi (solo i batteri) all'organismo e quindi generano reazioni anomale le piu' disparate ed inaspettate; e' il principio stesso dell'atto vaccinale ad essere discusso e RIGETTATO in toto !

Gli esperti di vaccini del CDC, hanno spesso conflitti di interesse - 18/03/2010
CDC e Conflitti di interesse - 1 + CDC e Conflitti di interesse - 2 + CDC e Conflitti di interesse - 3 + Corruzione + Danni dei Vaccini + Contro Immunizzazione

CDC conflitti di interesse anche per i vaccini + anche per la FDA
http://healthimpactnews.com/2014/cdcs-purchase-of-4-billion-of-vaccines-a-conflict-of-interest-in-overseeing-vaccine-safety/

Davvero inquietante !
Questo medico il Dott. Andrew Moulden è MORTO (probabilmente assassinato) in modo inspiegabile nel novembre 2013 al età di 49, subito dopo aver pubblicato Le SUE RICERCHE che DIMOSTRANO il DANNO CAUSATO dai VACCINI, RICONOSCIBILI SOLO da un SEMPLICE ESAME ESTERNO
http://vaccineimpact.com/2015/dr-andrew-moulden-learning-to-identify-vaccine-damage/ 

Parlamentari pagati dalle Lobbies ? - Roma Ott. 2013 
L'intervista a un assistente di un Senatore che svelerebbe i traffici illeciti tra parlamentari e Lobbies.
Video dell'intervista: 
http://www.video.mediaset.it/video/iene/puntata/390060/roma-parlamentari-pagati-dalle-lobbies.html

Informatore dei CDC CONFESSA la FRODE e le FALSIFICAZIONI sugli studi della correlazione VACCINO=AUTISMO

Sentenza 2012 - Trib. Rimini su Vaccini=Autismo

Commento NdR: sulla sentenza di Rimini: vaccini = autismo
BENE ha fatto il Giudice del Tribunale di Rimini (Italia) a sentenziare in quel modo, perche' egli non  si e' lasciato influenzare dalle FALSITA' del Ministero della "salute" (che e' stato da noi informato sui Danni dei vaccini dal 1996 e se ne sta zitto.....assieme a tutti gli altri "enti"....)  fino agli ordini dei medici......tutti al servizio di Big Pharma ! - vedi lo studio del dott.: Wakefield.htm

vedi: Amish senza autismo perche' NON vaccinano + 1000 studi sui Danni dei Vaccini  +  Bibliografia 3 Bibliografia 4  + Sostanze eterologhe nei vaccini e reazioni  +  Autismo  Big Pharma  + INGREDIENTI TOSSICI anche OCCULTI, di alcuni VACCINI analizzati + Contenuto nel vaccini Trivalenti (difpertal)  +  Come si producono i Vaccini + Falsita' della medicina ufficiale  

Negli USA dal 1988 le vaccinazioni si sono triplicate ed i casi di Autismo sono aumentati del 270 % !!
Il libro ormai esaurito, del dott. Massimo Montinari
NO Vaccini, no Autismo: http://homefirst.com/no_vaccines_no_autism
Killing Us Softly (non e’ in italiano): http://www.youtube.com/watch?v=Pjt77lBNjwM&feature=related

1. Hepatitis B Vaccination of Male Neonates and Autism
Annals of Epidemiology, September 2009
CM Gallagher, MS Goodman, Stony Brook University Medical Center
Boys vaccinated as neonates had threefold greater odds for autism diagnosis compared to boys never vaccinated or vaccinated after the first month of life.

2. Porphyrinuria in childhood autistic disorder: Implications for environmental toxicity
Toxicology and Applied Pharmacology, 2006
Robert Natafa, et al, Laboratoire Philippe Auguste, Paris, France
These data implicate environmental toxicity in childhood autistic disorder.

3. Theoretical aspects of autism: Causes—A review
Journal of Immunotoxicology, January-March 2011
Helen V. Ratajczak, PhD
Autism could result from more than one cause, with different manifestations in different individuals that share common symptoms. Documented causes of autism include genetic mutations and/or deletions, viral infections, and encephalitis following vaccination.

4. Uncoupling of ATP-mediated Calcium Signaling and Dysregulated IL-6 Secretion in Dendritic Cells by Nanomolar Thimerosal
Environmental Health Perspectives, July 2006.
Samuel R. Goth, Ruth A. Chu Jeffrey P. Gregg
This study demonstrates that very low-levels of Thimerosal can contribute to immune system disregulation.

5. Gender-selective toxicity of thimerosal
Exp Toxicol Pathol. 2009 Mar;61(2):133-6. Epub 2008 Sep 3. 
Branch DR, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto
A recent report shows a correlation of the historical use of thimerosal in therapeutic immunizations with the subsequent development of autism; however, this association remains controversial. Autism occurs approximately four times more frequently in males compared to females; thus, studies of thimerosal toxicity should take into consideration gender-selective effects. The present study was originally undertaken to determine the maximum tolerated dose (MTD) of thimersosal in male and female CD1 mice. However, during the limited MTD studies, it became apparent that thimerosal has a differential MTD that depends on whether the mouse is male or female.

6. Comparison of Blood and Brain Mercury Levels in Infant monkeys exposed to Vaccines Containing Thimerosal
Environmental Health Perspectives, Aug 2005. 
Thomas Burbacher, PhD, University of Washington
This study demonstrates clearly and unequivocally that ethyl mercury, the kind of mercury found in vaccines, not only ends up in the brain, but leaves double the amount of inorganic mercury as methyl mercury, the kind of mercury found in fish. This work is groundbreaking because little is known about ethyl mercury, and many health authorities have asserted that the mercury found in vaccines is the “safe kind.” This study also delivers a strong rebuke of the Institute of Medicine’s recommendation in 2004 to no longer pursue the mercury-autism connection.

7. Increases in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methyl mercury exposure
Toxicology and Applied Pharmacology, 1994 
Charleston JS et al, Department of Pathology, School of Medicine, University of Washington
The identities of the reactive glial cells and the implications for the long-term function and survivability of the neurons due to changes in the glial population following subclinical long-term exposure to mercury are discussed.

8. Neuroglial Activation and Neuroinflammation in the Brain of Patients with Autism 
Annals of Neurology, Feb 2005.
Diana L. Vargas, MD [Johns Hopkins University]
This study, performed independently and using a different methodology than Dr. Herbert (see above) reached the same conclusion: the brains of autistic children are suffering from inflammation.

9. Autism: A Brain Disorder, or a Disorder That Affects the Brain? 
Clinical Neuropsychiatry, 2005 
Martha R. Herbert M.D., Ph.D., Harvard University
Autism is defined behaviorally, as a syndrome of abnormalities involving language, social reciprocity and hyperfocus or reduced behavioral flexibility. It is clearly heterogeneous, and it can be accompanied by unusual talents as well as by impairments, but its underlying biological and genetic basis in unknown. Autism has been modeled as a brain-based, strongly genetic disorder, but emerging findings and hypotheses support a broader model of the condition as a genetically influenced and systemic.

10. Activation of Methionine Synthase by Insulin-like Growth Factor-1 and Dopamine: a Target for Neurodevelopmental Toxins and Thimerosal
Molecular Psychiatry, July 2004. 
Richard C. Deth, PhD [Northeastern University]
This study demonstrates how Thimerosal inhibits methylation, a central driver of cellular communication and development.

11. Validation of the Phenomenon of Autistic Regression Using Home Videotapes
Archives of General Psychiatry, 2005 
Emily Werner, PhD; Geraldine Dawson, PhD, University of Washington
Conclusion This study validates the existence of early autistic regression.

12. Blood Levels of Mercury Are Related to Diagnosis of Autism: A Reanalysis of an Important Data Set
Journal of Child Neurology, 2007 
M. Catherine DeSoto, PhD, Robert T. Hitlan, PhD -Department of Psychology, University of Northern Iowa
Excerpt: “We have reanalyzed the data set originally reported by Ip et al. in 2004 and have found that the original p value was in error and that a significant relation does exist between the blood levels of mercury and diagnosis of an autism spectrum disorder. Moreover, the hair sample analysis results offer some support for the idea that persons with autism may be less efficient and more variable at eliminating mercury from the blood.”

13. Developmental Regression and Mitochondrial Dysfunction in a Child With Autism
Journal of Child Neurology, February 2006 
Jon S. Poling, MD, PhD, Department of Neurology and Neurosurgery, Johns Hopkins Hospital
Excerpt: “Children who have (mitochondrial-related) dysfunctional cellular energy metabolism might be more prone to undergo autistic regression between 18 and 30 months of age if they also have infections or immunizations at the same time.”

14. Oxidative Stress in Autism: Elevated Cerebellar 3-nitrotyrosine Levels
American Journal of Biochemistry and Biotechnology, 2008 
Elizabeth M. Sajdel-Sulkowska, – Dept of Psychiatry, Harvard Medical School
Excerpt: The preliminary data suggest a need for more extensive studies of oxidative stress, its relationship to the environmental factors and its possible attenuation by antioxidants in autism.”

15. Large Brains in Autism: The Challenge of Pervasive Abnormality
The Neuroscientist, 2005. 
Martha Herbert, MD, PhD, Harvard University
This study helps refute the notion that the brains of autistic children are simply wired differently and notes, “neuroinflammation appears to be present in autistic brain tissue from childhood through adulthood.” Dr. Herbert suggests that chronic disease or an external environmental source (like heavy metals) may be causing the inflammation.

16. Evidence of Toxicity, Oxidative Stress, and Neuronal Insult in Autism
Journal of Toxicology and Environmental Health, Nov-Dec 2006. 
Janet Kern, Anne Jones, Department of Psychiatry, University of Texas Southwestern Medical Center
“This article discusses the evidence for the case that some children with autism may become autistic from neuronal cell death or brain damage sometime after birth as result of insult; and addresses the hypotheses that toxicity and oxidative stress may be a cause of neuronal insult in autism… the article discusses what may be happening over the course of development and the multiple factors that may interplay and make these children more vulnerable to toxicity, oxidative stress, and neuronal insult.”

17. Oxidative Stress in Autism
Pathophysiology, 2006. 
Abha Chauhan, Ved Chauhan
This study provides a helpful overview of the growing evidence supporting the link between oxidative stress and autism.

18. Thimerosal Neurotoxicity is Associated with Glutathione Depletion: Protection with Glutathione Precursors
Neurotoxicology, Jan 2005. 
S. Jill James, PhD, University of Arkansas
This recent study demonstrates that Thimerosal lowers or inhibits the body’s ability to produce Glutathione, an antioxidant and the body’s primary cellular-level defense against mercury.

19. Aluminum adjuvant linked to gulf war illness induces motor neuron death in mice
Neuromolecular Medicine, 2007 
Christopher Shaw, Ph.D., Department of Ophthalmology and Program in Neuroscience, University of British Columbia
This study demonstrates the extreme toxicity of the aluminum adjuvant used as a preservative in vaccines.

20. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas
Health & Place, 2006 
Raymond F. Palmer, University of Texas Health Science Center
This study demonstrated the correlation between environmental mercury and autism rates in Texas.

21. Autism Spectrum Disorders in Relation to Distribution of Hazardous Air Pollutants in the SF Bay Area
Environmental Health Perspectives, September, 2006 
Gayle Windham, Div. of Environmental and Occupational Disease Control, California Department of Health Services
Excerpt: “Our results suggest a potential association between autism and estimated metal concentrations, and possibly solvents, in ambient air around the birth residence.”

22. A Case Series of Children with Apparent Mercury Toxic Encephalopathies Manifesting with Clinical Symptoms of Regressive Autistic Disorder
Journal of Toxicology and Environmental Health, 2007 
David A. Geier, Mark R. Geier
This study reviewed the case histories and medical profiles of nine autistic children and concluded that eight of the nine children were mercury toxic and this toxicity manifested itself in a manner consistent with Autism Spectrum Disorders.

23. Attention-deficit hyperactivity disorder and blood mercury level: a case-control study in chinese children
Neuropediatrics, August 2006 – P.R. Kong
Excerpt: “There was significant difference in blood mercury levels between cases and controls, which persists after adjustment for age, gender and parental occupational status. The geometric mean blood mercury level was also significantly higher in children with inattentive and combined subtypes of ADHD. High blood mercury level was associated with ADHD. Whether the relationship is causal requires further studies.”

24. The Changing Prevalence of Autism In California
Journal of Autism and Developmental Disorders, April 2003 
Mark F. Blaxill, David S. Baskin, and Walter O. Spitzer
This study helps to refute the supposition made by some researchers that autism’s epidemic may only be due to “diagnostic substitution”.

25. Mitochondrial Energy-Deficient Endophenotype in Autism
American Journal of Biochemistry and Biotechnology 2008 
J. Jay Gargus and Faiqa Imtiaz, School of Medicine, University of California, Irvine,
While evidence points to a multigenic etiology of most autism, the pathophysiology of the disorder has yet to be defined and the underlying genes and biochemical pathways they subserve remain unknown.

26. Bridging from Cells to Cognition in Autism Pathophysiology: Biological Pathways to Defective Brain Function and Plasticity
American Journal of Biochemistry and Biotechnology 2008 
Matthew P. Anderson, Brian S. Hooker and Martha R. Herbert, Cambridge Health Alliance/Harvard Medical School/Beth Israel Deaconess Medical Center
We review evidence to support a model where the disease process underlying autism may begin when an in utero or early postnatal environmental, infectious, seizure, or autoimmune insult triggers an immune response that increases reactive oxygen species (ROS) production in the brain that leads to DNA damage (nuclear and mitochondrial) and metabolic enzyme blockade and that these inflammatory and oxidative stressors persist beyond early development (with potential further exacerbations), producing ongoing functional consequences.

27. Heavy-Metal Toxicity—With Emphasis on Mercury
John Neustadt, ND, and Steve Pieczenik, MD, PhD
Conclusion: Metals are ubiquitous in our environment, and exposure to them is inevitable. However, not all people accumulate toxic levels of metals or exhibit symptoms of metal toxicity, suggesting that genetics play a role in their potential to damage health.

28. Evidence of Mitochondrial Dysfunction in Autism and Implications for Treatment
American Journal of Biochemistry and Biotechnology
Daniel A. Rossignol, J. Jeffrey Bradstreet
MtD and oxidative stress may also explain the high male to female ratio found in autism due to increased male vulnerability to these dysfunctions.

29. Proximity to point sources of environmental mercury release as a predictor of autism prevalence
Health & Place, 2008 
Raymond F. Palmer et al, University of Texas Health Science Center
This study should be viewed as hypothesis-generating – a first step in examining the potential role of environmental mercury and childhood developmental disorders. Nothing is known about specific exposure routes, dosage, timing, and individual susceptibility. We suspect that persistent low-dose exposures to various environmental toxicants, including mercury, that occur during critical windows of neural development among genetically susceptible children (with a diminished capacity for metabolizing accumulated toxicants) may increase the risk for developmental disorders such as autism.

30. Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions
Developmental Medicine & Child Neurology, 2007 
Guiomar Oliveira MD PhD et al, Centro de Desenvolvimento da Criança, Hospital Pediátrico de Coimbra; Assunção Ataíde BSc, Direcção Regional de Educação do Centro Coimbra;
The objective of this study was to estimate the prevalence of autistic spectrum disorder (ASD) and identify its clinical characterization, and medical conditions in a paediatric population in Portugal
Fonte:
http://circleofdocs.com/30-solid-scientific-studies-that-prove-vaccines-cause-autism/ 


LA VALANGA DEI NUOVI STUDI DI CORRELAZIONE AUTISMO-MERCURIO + Autismo Referenze 2 + Autismo - 3
J Immunotoxicol. 2011 Jan-Mar;8(1):68-79.
Theoretical aspects of autism: causes--a review. Ratajczak HV - Source: hratajcz@comcast.net

Abstract
Autism, a member of the pervasive developmental disorders (PDDs), has been increasing dramatically since its description by Leo Kanner in 1943. First estimated to occur in 4 to 5 per 10,000 children, the incidence of autism is now 1 per 110 in the United States, and 1 per 64 in the United Kingdom, with similar incidences throughout the world. Searching information from 1943 to the present in PubMed and Ovid Medline databases, this review summarizes results that correlate the timing of changes in incidence with environmental changes. Autism could result from more than one cause, with different manifestations in different individuals that share common symptoms. Documented causes of autism include genetic mutations and/or deletions, viral infections, and encephalitis following vaccination. Therefore, autism is the result of genetic defects and/or inflammation of the brain. The inflammation could be caused by a defective placenta, immature blood-brain barrier, the immune response of the mother to infection while pregnant, a premature birth, encephalitis in the child after birth, or a toxic environment.

Comment
Response to "Theoretical aspects of autism: causes--a review" by Ratajczak, HV (Journal of Immunotoxicology 8:68-79, 2011). [J Immunotoxicol. 2011]
Response to "Theoretical aspects of autism: causes--a review" by Ratajczak, HV (Journal of Immunotoxicology 8:68-79, 2011).Dewitt JC, Dietert RR. J Immunotoxicol. 2011 Jul-Sep; 8(3):195-7. Epub 2011 May 31.
Coincidental associations do not provide proof for the etiology of autism. [J Immunotoxicol. 2011]
Coincidental associations do not provide proof for the etiology of autism.Kennedy JS, Lawrence DA. J Immunotoxicol. 2011 Jul-Sep; 8(3):198-203. Epub 2011 Jun 16.
PMID: 21299355 [PubMed - indexed for MEDLINE]


Traduzione:
J Immunotoxicol. 2011 Gen-Mar, 8 (1) :68-79.
Aspetti teorici dell'autismo: cause - una recensione. By Ratajczak HV - Fonte: hratajcz@comcast.net
Estratto
Autismo, un membro dei disturbi pervasivi dello sviluppo (PDD), è aumentata drammaticamente dalla sua descrizione da parte di Leo Kanner nel 1943. Prima era stimato in 4 o 5 ogni 10.000 bambini, l'incidenza oggi (2010) dell'autismo è 1 per 110 negli Stati Uniti, e 1 per 64 nel Regno Unito, con incidenze simili in tutto il mondo.
Ricerca di informazioni dal 1943 ad oggi su PubMed e Ovid banche dati Medline, questa recensione riassume i risultati che correlano i tempi di cambiamento nell'incidenza con i cambiamenti ambientali.
L’Autismo potrebbe derivare da più di una causa, con manifestazioni differenti in differenti individui che condividono sintomi comuni.
Cause documentate di autismo comprendono mutazioni genetiche e / o delezioni, infezioni virali, e in seguito ad encefalite da vaccinazione.
Pertanto, l'autismo è il risultato di difetti genetici e/o infiammazione del cervello.
L'infiammazione può essere causata anche da un difetto placenta, immaturita' della barriera emato-encefalica, la risposta immunitaria della madre ad infezione durante la gravidanza, un parto prematuro, encefalite nel bambino dopo la nascita, od in un ambiente tossico.
Commenti
Risposta a "Aspetti teorici dell'autismo: cause - una recensione" di Ratajczak, HV (Journal of Immunotossicologia 8:68-79, 2011). [J Immunotoxicol. 2011]
Risposta a "Aspetti teorici dell'autismo: cause - una recensione" di Ratajczak, HV (Journal of Immunotossicologia 8:68-79, 2011) Dewitt JC, RR. Dietert. J Immunotoxicol. 2011 Lug-Set, 8 (3) :195-7. Epub 2011 Maggio 31.
Associazioni coincidenti non forniscono prova per l'eziologia dell'autismo. [J Immunotoxicol. 2011]
Associazioni coincidenti non forniscono prova per l'eziologia dell'autismo. Kennedy JS, Lawrence DA.
J Immunotoxicol. 2011 Lug-Set, 8 (3) :198-203. Epub 2011 Jun 16.
PMID: 21299355 [PubMed - indexed for MEDLINE]


Studio rivela un'associazione positiva tra autismo e vaccini - Giu. 2011
Un recente studio (pubblicazione online: 26 mag. 2011) pubblicato sul Journal of Rapport sulla salute e Tossicologia Ambientale, di cui il titolo del report, che un'associazione positiva è stata trovata tra autismo e vaccini: un'associazione positiva trovata tra Prevalenza autismo Vaccinazioni dell'infanzia e l'assorbimento attraverso la popolazione degli Stati Uniti .
L'abstract studio attribuisce la conclusione, nel contesto del pensiero attuale che vede l'autismo come l'interazione tra predisposizione genetica e fattori ambientali. Essa individua anche i difetti in alcuni degli studi più importanti che sono propagandati come "debunking" ogni possibile collegamento vaccino autismo.
To cite this Article DeLong, Gayle(2011) 'A Positive Association found between Autism Prevalence and Childhood Vaccination uptake across the U.S. Population', Journal of Toxicology and Environmental Health, Part A, 74: 14, 903 —916
To link to this Article: DOI: 10.1080/15287394.2011.573736
URL: http://dx.doi.org/10.1080/15287394.2011.573736 - vedi: QUI il PDF

The body detoxifies itself (James et al. 2004).
This difficulty in detoxifying could be associated with metals from vaccines being sequestered in the brain and causing neurological damage (Kern et al. 2007).
Vaccines may also increase the oxidative stress of children with preexisting mitochondrial dysfunctions to such an extent that the children develop autism (Poling et al. 2006).
In general, susceptibility to developing a neurological disability after exposure to an environmental insult such as a vaccine depends on factors such as a child¡¯s age at time of exposure, amount of exposure, genetic predisposition, and stress (Kern and Jones 2006).
Compounding these biological issues is the fact that the number of vaccinations recommended for U.S. children by age 2 years has more than tripled, from 8 vaccinations in 1983 to 27 in 2010 (Centers for Disease Control and Prevention 1983; 2010). Although individual vaccines are tested for safety and efficacy, no study has ever examined the safety of the entire vaccination schedule recommended for U.S. children by the CDC. Neither the short-term nor chronic interactions among all the vaccines in a childs recommended schedule have ever been tested.
Examining the relationship between the proportion of children who receive vaccinations and the prevalence of autism may provide insights into whether autism is an adverse reaction to vaccinations. If an association between receiving vaccinations and developing autism is  found to exist across geography and through time, further investigation into the hypothesis is warranted.


Il danno da vaccini è una causa documentata di autismo
E' stata pubblicata in questi giorni  sulla importante rivista scientifica Journal of Immunotoxicology, 2011; 8(1): 68–79, una nuova revisione di studi che esamina le varie cause ambientali dell'autismo, tra cui i vaccini e i loro componenti.

Leggere il  pdf:

Helen Ratajczak, l'autrice, è una ricercatrice della Boehringer Ingelheim Pharmaceuticals che ha pubblicato, come autrice o coautrice, 41 articoli su PubMed. E' anche stata coautrice nel 2006 di uno studio per l'FDA e, nello stesso anno, è stata eletta  Presidente della sezione Nord Est dell'Istituto di Tossicologia. E' una scienziata seria e rispettata che, in questa recensione.
Discute la presenza di DNA di feti umani nell' MMR II e nei vaccini Varivax. Questi alcuni stralci dal suo lavoro sull'autismo su  Immunotoxicology:

ABSTRACT
L'autismo può risultare da più di una causa, con differenti manifestazioni in differenti soggetti che mostrano sintomi comuni.
Le cause documentate di autismo  comprendono mutazioni genetiche e/o delezioni, infezioni virali e encefaliti in seguito a vaccinazioni. 

L'AUMENTO della DIFFUSIONE dell'ASD E' una REALTA'
In generale, l'incremento della diffusione dell'autismo non deve considerarsi il risultato della avvenuta  riclassificazione.
Sebbene le diagnosi di autismo siano aumentate, non c'è infatti alcuna diminuzione corrispondente in altre categorie diagnostiche, i dati del Ministero dell'Istruzione, e in particolare quelli provenienti dal Dipartimento per l'Istruzione Speciale, mostrano un significativo aumento della diffusione dell'autismo tra i bambini, e specialmente tra quelli nati tra il 1987 e il 1992. In quegli anni, la diffusione dell'autismo su 10.000 nati salì di circa il 50% ogni 2 anni: 5.3 nel 1984, 7.8 nel 1986, 11.8 nel 1988, e 18.3 nel1990.
In quel periodo non ci furono cambiamenti nella diffusione di ritardo mentale, ritardo del linguaggio o di lesione cerebrale, la qual cosa indica che l'aumento dell'autismo c'è effettivamente stato.
La nuova versione del vaccino contro morbillo, rosolia e parotite  (MMR II) che non contiene Thimerosal venne introdotta nel 1979.
Dal 1983, venne utilizzata solo questa nuova versione.
L'autismo negli Stati Uniti  ebbe un drammatico picco tra il 1983 e il1990 passando da 4–5 casi ogni 10.000 nati a 1 su 500.
Nel 1988, venivano consigliate due dosi dell'MMR II per immunizzare quei soggetti che non rispondevano al primo vaccino. Un picco nella diffusione dell'autismo venne quindi ad associarsi all'aggiunta della seconda dose di MMR II.

Nel 1988, l'MMR II venne usato anche in Inghilterra nella quale oggi il tasso di diffusione è arrivato a 1 ogni 64.
Anche in Canada, Danimarca e Giappone si sono avuti importanti incrementi della diffusione dell'autismo. E' importante notare che diversamente dal primo MMR, la componente per la rosolia dell' MMR II è stata propagata in membrana cellulare umana derivata da tessuti dei polmoni embrionali (Merck and Co., Inc., 2010).

Il vaccino  MMR II è contaminato con DNA umano proveniente dalla membrana cellulare. Questo DNA umano potrebbe essere la causa del picco nella diffusione dell'autismo. 
Un successivo picco si ebbe poi nel 1995 quando il vaccino per la varicella venne fatto crescere in tessuti fetali umani  (Merck and Co., Inc., 2001; Breuer, 2003). L'attuale incidenza negli Stati Uniti è approssimativamente di 1 su 80 (anno 2008).

Il DNA umano dai vaccini può essere inserito casualmente nei geni di chi ha fatto il vaccino da ricombinazioni omologhe, un processo che avviene spontaneamente solo all'interno di una specie.
Punti caldi per l'inserimento di questo DNA sono stati trovati nel cromosoma X in otto geni associati all'autismo coinvolti nella formazione di sinapsi nei nervi, nello sviluppo del sistema nervoso centrale e nella funzione mitocondriale (Deisher, 2010).
Tutto questo potrebbe fornire delle spiegazioni del perchè l'autismo è in predominanza una malattia che colpisce maggiormente  i maschi. Messi assieme, questi dati sostengono l'ipotesi che residui di DNA umano in alcuni vaccini possano provocare autismo.

VACCINI

I dati sull'incidenza e prevalenza indicano che il momento di introduzione dei vaccini e le modificazioni nel tipo e nell'incremento del numero dei vaccini inoculati contemporaneamente implica che i vaccini sono causa di autismo.
La tabella attuale raccomandata per l'immunizzazione per bambini dai 0 ai 6 anni negli Stati Uniti include sei vaccini ai due mesi di età e 9 a 12-15 mesi, un incremento che va oltre le raccomandazioni di sei anni prima.

Il sistema immunitario è particolarmente sensibile a due mesi di età. In questo modo, il sistema immunitario di un neonato viene compromesso a due mesi. Una minaccia attraverso così tanti vaccini nel momento in cui il sistema immunitario è compromesso può contribuire all'insorgenza dell'autismo.
ANTIGENI VACCINALI
Molti genitori affermano che lo sviluppo dei loro figli era normale finchè non hanno fatto i vaccini all'età di circa 18 mesi. L'organismo  vaccino potrebbe esserne la causa. Una ipotesi, relativa al vaccino della pertosse è che la tossina pertosse contenuta in questo vaccino causi una separazione della proteina G-alpha dai recettori retinoidi in bambini geneticamente a rischio.
RIEPILOGO e CONCLUSIONI
L'autismo ha raggiunto proporzioni epidemiche. Con una diffusione di 1 su110 negli Stati Uniti, 1 su 64 in Inghilterra e  United Kingdom, e numeri simili in molti altri paesi, è evidente una situazione di pericolo per le future generazioni. Integrando i dati qui presentati,  una ipotesi è che l'autismo sia il risultato di difetti genetici, con l'effetto contributivo dell'età avanzata dei genitori, e/o infiammazione del cervello. L'infiammazione potrebbe essere causata da un gran numero di agenti tossici  ambientali, infezioni e co-morbidità in soggetti geneticamente  predisposti ai disordini dello sviluppo.
 
Tratto da: emergenzaautismo.org

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

N Engl J Med. 2002 Nov 7;347(19):1477-82.
A population-based study of measles, mumps, and rubella vaccination and autism.
Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M.
Source: Danish Epidemiology Science Center, Department of Epidemiology and Social Medicine, Arhus, Denmark. kmm@dadlnet.dk
Abstract

BACKGROUND:
It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

METHODS:
We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998.
The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

RESULTS:
Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders.
After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

CONCLUSIONS:
This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
Copyright 2002 Massachusetts Medical Society

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Collegamento Scientifico tra Autismo e Vaccini - per il meccanismo dei danni dei vaccini
Il Center for Modeling Optimal Outcomes ha fatto una sorprendente scoperta mentre stava svolgendo una ricerca sull’applicazione della neuroscienza nel business.
Il Centro ha scoperto delle relazioni uniche tra le varie sostanze chimiche del cervello (neuroormoni, neutrotrasmettitori, ecc.) e ha provato ad applicare questo modello alla letteratura scientifica.
Con stupore questo gruppo di studiosi ha così scoperto che questo modello di relazioni poteva essere applicato ai processi scientifici per mantenere l’equilibrio (relazioni omeostatiche) in tutti i campi della scienza, dalle particelle subatomiche, alla chimica, alle sostanze biologiche.
L’intera comunità scientifica sa che l’omeostasi esiste, ma questa conoscenza non era ancora stata convertita in un modello replicabile, passo dopo passo. Il Centro ora ha identificato con precisione tale processo esplicito. Studiando in particolare l’autismo, il gruppo del Center's Life Sciences è stato in grado di formulare un modello scientificamente verificabile per un altamente probabile percorso causale dell’autismo.
Applicando il loro modello, è diventato apparente che l’autismo è un risultato di diverse variabili e che quando la relazione omeostatica di ciascuna di queste variabili viene distrutta, si forma lo scenario di una “tempesta perfetta” che dà come risultato l’autismo.
L’applicazione del modello ha identificato diverse variabili che spiegano la proporzione superiore maschile di malati di autismo (4 maschi a 1 femmina) e spiegano perché non tutti i bambini maschi si ammalano di autismo.

Ora la comunità scientifica dovrà validare queste scoperte ma, secondo il Centro, il modello di verifica delle relazioni omeostatiche indica che il fattore scatenante dell’autismo sia uno sbilanciamento tra una coppia di aminoacidi neurotrasmettitori, il glutamato e la glicina.
William McFaul, il fondatore del Centro, ha dichiarato: “Se non fosse stato per i genitori che insistevano dicendo che i vaccini sono responsabili della condizione dei loro figli, non avremmo mai scoperto che lo stabilizzatore del vaccino MMR e di qualche altro vaccino è la gelatina idrolizzata, una sostanza composta per il circa il 21% da glicina.
Appare chiaro che, basandosi su una scienza facilmente verificabile, l’uso di quella forma di glicina scateni uno sbilanciamento nei neurotrasmettitori aminoacidi responsabili del tasso di assorbimento di alcune classi di cellule in tutto il corpo.
E’ proprio questa distruzione ad ampio spettro che risulterebbe nei problemi sistemici che affliggono la mente e il corpo e che vengono attualmente definiti come autismo “classico”. L’utilizzo del nostro modello indica che ciascuno dei disturbi nello spettro autistico (ASD) è attribuibile a differenti distruzioni nell’omeostasi.”
Il Centro ora sta cercando di affiliarsi ai centri accademici per fornire il proprio modello alla comunità scientifica che avrà, a sua volta, le risorse per studiare in maniera più approfondita questa scoperta e diffonderla.
Tratto da: autismovaccini.splinder.com

Commento NdR: cosa causa l'alterazione della omeostasi ?....specialmente i vaccini, c on le loro sostanze tossiche, ne sono maggiormente responsabili, in quanto alterano le funzioni cellulari e quindi tissutali...con le conseguenze del caso !

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Catepsina D e l'apoptosi proteine correlate sono elevati nel cervello dei soggetti autistici
By Sheikh AM, Li X, G Wen, Tauqeer Z, WT Brown, Malik M. - Neuroscienze. 2010 gen 20; 165 (2) :363-70. EPub.
Articolo originale: http://www.ncbi.nlm.nih.gov/pubmed/19854241
L'autismo è un grave disturbo neurologico caratterizzato da problemi di comunicazione, abilità sociali e comportamenti ripetitivi. Studi recenti suggeriscono che i meccanismi di apoptosi può in parte contribuire alla patogenesi di questo disturbo. Catepsina D è la proteasi lisosomiali e predominante è abbondantemente espresso nel cervello. Essa svolge un ruolo importante nella regolazione dell'apoptosi cellulare e ha mostrato di mediare l'apoptosi indotta dal fattore di necrosi tumorale citochine (TNF)-alfa e interferone (IFN)-gamma. In questo studio, abbiamo esaminato i livelli di espressione di catepsina D nel cervello autistico. Abbiamo scoperto che l'espressione della proteina catepsina D è risultato significativamente aumentato nella corteccia frontale, nelle cellule piramidali e granello dell'ippocampo, e nei neuroni del cervelletto nei soggetti autistici rispetto ai controlli. Inoltre, abbiamo scoperto che l'espressione della proteina anti-apoptotica Bcl-2 era significativamente diminuito, mentre caspasi-3, un boia critico di apoptosi, è stato aumentato nel cervelletto di soggetti autistici. In precedenza i nostri studi hanno dimostrato che Bcl-2 è diminuita e il Akt-Bcl-2 BDNF percorso è compromesso nella corteccia frontale dei soggetti autistici, che ha suggerito che l'apoptosi aumentata possono essere coinvolti nella patogenesi dell'autismo.
La nostra scoperta attuale di diminuzione delle Bcl-2 e una maggiore capase-3 nel cervelletto di soggetti autistici inoltre sostiene questa proposta. Inoltre, il ritrovamento di catepsina D aumentato nel cervelletto di soggetti autistici suggerisce che, attraverso la sua regolazione dell'apoptosi, l'attività della catepsina D alterato nel cervello autistico può svolgere un ruolo importante nella patogenesi dell'autismo.
vedi: Cellule + Meccanismo dei danni dei Vaccini - Polio dai vaccini


>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Leucociti (globuli bianchi) del sangue periferico, di produzione di BDNF in seguito a stimolazione mitogene a esordio precoce e autismo regressivo
By Enstrom A et al. - American Journal of Biochimica e Biotecnologie 4 (2): 121-129, 2008
http://www.scipub.org/fulltext/ajbb/ajbb42121-129.pdf
Il Brain-derived neurotrophic factor (BDNF) è fondamentale per la differenziazione neuronale e lo sviluppo sinaptico. BDNF è anche implicata nello sviluppo di disturbi psicologici inclusi depressione, disturbo bipolare e schizofrenia.
In precedenza, elevati livelli di BDNF sono stati osservati in campioni di sangue neonatale dei neonati che sono stati successivamente diagnosticati con autismo rispetto ai bambini che si sono sviluppati normalmente, suggerendo che il BDNF potrebbero essere coinvolto nello sviluppo di autismo.
BDNF viene prodotto dalle cellule microgliali attivate nel cervello, un fenotipo cellulare che dispone di diverse parti con macrofagi periferici, suggerendo un ruolo importante per il sistema immunitario nella produzione di BDNF.
Abbiamo ipotizzato che sotto la stimolazione mitogenica, le cellule mononucleate del sangue periferico ottenute da bambini con autismo possa aver alterato la produzione di BDNF rispetto agli altri bambini di pari età con i soggetti di controllo. Inoltre, abbiamo esaminato le differenze tra la produzione di BDNF in classico / autismo ad esordio precoce e bambini che erano una forma di autismo regressivo.
Mostriamo qui che i livelli plasmatici dei livelli di BDNF sono aumentati nei bambini con autismo, soprattutto nei soggetti ad esordio precoce dell'autismo. Inoltre, ai sensi mitogenica stimolazione con PHA e LPS, la produzione di BDNF è significativamente aumentata nei bambini con autismo rispetto ai soggetti con sviluppo normale.
Tuttavia, la stimolazione con tossoide tetanico si traduce in una diminuzione della risposta nei bambini con autismo.
Questi dati suggeriscono che la produzione di cellule immunitarie derivate di BDNF potrebbero essere una fonte importante per l'aumento del BDNF che viene rilevato in alcuni soggetti con autismo.
Come un fattore neurotrofico prodotto da cellule del sistema immunitario, BDNF potrebbe contribuire a spiegare il ruolo del sistema immunitario nella manutenzione neurosviluppo e cellule neuronali, che possono essere sregolati nell'autismo.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Analisi nella famiglia, delle classi e sottoclassi di immunoglobuline nei bambini con disturbo autistico
By Spiroski M et al. - Istituto di Immunobiologia e Genetica Umana, Facoltà di Medicina, 1109 Skopje, PO Box 60, Macedonia. - Bosn J Med Sci di base. 2009 Nov; 9 (4) :283-9.

Il disturbo Autistico è un disordine dello sviluppo neurologico grave caratterizzata da una triade di menomazioni dell'interazione sociale reciproca, la comunicazione verbale e non verbale, e un modello di ripetitivi stereotipati attività, comportamenti e interessi.
Ci sono linee di forza di prove che suggeriscono che il sistema immunitario ha un ruolo importante nella patogenesi del disturbo autistico.
Lo scopo di questo studio era quello di analizzare la concentrazione plasmatica quantitativa delle classi di immunoglobuline, e sottoclassi di pazienti autistici e delle loro famiglie.
L'indagine è stata effettuata a posteriori in 50 persone con disturbo autistico nella Repubblica di Macedonia. Infantile disturbo autistico è stato diagnosticato dal DSM-IV e ICD-10 criteri. classi di immunoglobuline del plasma (IgM, IgA e IgG) e sottoclassi (IgG1, IgG2, IgG3 e IgG4) sono stati determinati utilizzando Nefelometro Analyzer BN-100. confronti multipli per la variabile di IgA hanno mostrato differenze statisticamente significative tra le tre coppie: autistici maschi dai padri (p = 0,001), autistici femminile dalle madri (p = 0.008), così come sorelle sani dai padri (p = 0.011) .
Differenze statisticamente significative tra tre gruppi per quanto riguarda disturbo autistico (persone con Disturbo Autistico, padre / madre di una persona con disturbo autistico, e il fratello / sorella), indipendentemente dal sesso appartiene a IgA, IgG2 e variabili IgG3. confronti multipli per la variabile di IgA hanno mostrato differenze statisticamente significative tra i bambini con disturbo autistico da padri e madri (p <0,001), ed i fratelli e le sorelle sani da padri e madri (p <0,001).
Confronto tra bambini sani e bambini affetti da disturbi autistici della stessa famiglia dovrebbero essere testati per classi e sottoclassi di immunoglobuline, al fine di evitare le differenze tra le generazioni.


>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Ridotti livelli di immunoglobuline nei bambini con autismo si correla con sintomi comportamentali
By Heuer L et al. - Università di California a Davis - Autismo Ris. 2008 Ott, 1 (5) :275-83.
Articolo originale: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663897/pdf/nihms97987.pdf

OBIETTIVI:
Per analizzare se i livelli plasmatici degli anticorpi in bambini con autismo o ritardo nello sviluppo (DD) differiscono da quelli con sviluppo tipico come un indicatore della funzione immunitaria e di correlare i livelli di anticorpi con la severità dei sintomi comportamentali. METODI: plasma è stato raccolto da bambini con disturbo autistico (UA; n = 116), DD, ma non autistici (n = 32), il disturbo dello spettro autistico, ma non completa l'autismo (n = 27), e di pari età in genere in via di sviluppo (TD) controlli (n = 96).
I campioni sono stati analizzati per livelli sistemici di immunoglobuline (IgG, IgM, IgA e IgE) da enzima-collegata dell'immunosorbente. I soggetti con autismo sono stati valutati usando l'Autism Diagnostic Observation Schedule e la Autism Diagnostic Interview-Revised, e tutti i soggetti sono stati valutati sul comportamento aberrante Checklist (ABC) dai genitori. punteggi numerici per ciascuna delle sottoscale ABC così come il punteggio totale sono quindi stati correlati con i livelli di Ig.

RISULTATI: I bambini con AU hanno un livello significativamente ridotto di IgG nel plasma (5,39 + / -0,29 mg / mL) rispetto al TD (7,72 + / -0,28 mg / mL, P <0,001) e dei bambini DD (8,23 + / -0,49 mg / mL, P <0,001). I bambini con autismo ha avuto anche un ridotto livello di plasma IgM (0.670.06 mg / mL) rispetto a TD (0,79 + / -0,05 mg / mL, P <0,05). Ig livelli erano correlati negativamente con i punteggi di ABC per tutti i bambini (IgG: r =- 0,334, p <0.0001; IgM: r =- 0,167, p = 0,0,285 mila).

CONCLUSIONE: I bambini con AU hanno ridotto significativamente i livelli plasmatici di IgG e IgM rispetto sia DD e controlli TD, suggerendo un difetto di fondo della funzione immunitaria. Questa riduzione di specifici livelli di Ig è correlata con la gravità del comportamento, in cui i pazienti con i punteggi più alti nella batteria comportamento hanno i livelli più ridotti di IgG e IgM.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Risposta immunitaria allergica nella sindrome di Asperger
By Magalhães ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, deAzevedo LC. - J Neuroimmunol. 2009 Nov 30; 216 (1-2) :108-12.
Articolo originale: http://www.ncbi.nlm.nih.gov/pubmed/19840888
La sindrome di Asperger è un sottogruppo di autismo caratterizzato da deficit sociali senza ritardo del linguaggio, e ad alte prestazioni cognitive. La natura biologica dell'autismo è ancora sconosciuta, ma ci sono prove controverse associando uno squilibrio immunitario e autismo. risultati clinici, comprese storia familiare atopica, i livelli sierici di IgE così come le prove cutanee hanno mostrato che l'incidenza di atopia è stata maggiore nel gruppo di Asperger rispetto ai controlli sani. Questi risultati suggeriscono che l'atopia è frequente in questo sottogruppo di autismo che implica che l'infiammazione allergica possa essere un elemento importante nella sindrome di Asperger.


>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

BIBLIOGRAFIA
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/  

Vaccini e rigonfiamento cerebrale
Iwasa S, "Rigonfiamento del cervello in topi causato dal vaccino anti-pertosse", Jpn J Med Sci Biol, 1985, 38(2):53-65
Mathur R, Kumari S, "-Fontanella protuberante- a seguito di vaccino triplo", Indian Pediatr, giugno 1981; 18(6): 417-418
Barry W, Hatcher G, "-Fontanelle protuberanti- in neonati senza meningite", Arch Dis Child, aprile 1989; 64(4): 635-636
Shendurnikar N, "-Fontanella protuberante- a seguito di vaccino DPT", Indian Pediatr, nov. 1986; 23(11): 960
Gross TP, Milstien JB, Kuritsky JN, "-Fontanella protuberante- a seguito di vaccinazione anti-difterica- tetano- pertosse e vaccino tetano- difterica", J Pediatr, marzo 1989;114(3):423-425
Jacob J, Mannino F, "Aumento di pressione intracraniale a seguito di vaccino anti- difterica, tetano e pertosse", Am J Dis Child, feb. 1979; 133(2):217-218
Dugmore, WN, "Edema bilaterale del polo posteriore: ipersensibilità al vaccino Alavac P", Br J Ophthalmol, dic. 1972, 55:848-849

Altra Bibliografie su Autismo dai Vaccini
Abell F, Krams M, Ashburner J, Passingham R, Friston K, Frackowiak R, Happé F, Frith C, Frith U, ‘The neuroanatomy of autism: a voxel-based whole brain analysis of structural scans’, NeuroReport, June 1999, Vol. 10, No. 8, 1647-1651

Adams CR, Ziegler DK, Lin JT, ‘Mercury intoxication simulating amyotrophic lateral sclerosis’, JAMA 1983; 250:642-643.
Al-Balaghi S, Möller E, Möller G, Abedi-Valugerdi M, ‘Mercury induces polyclonal B cell activation, autoantibody production and renal immune complex deposits in young (NZB x NZW) F1 hybrids’, Eur J Immunol, July 1996, 26(7):1519-1526
Alberti A, Pirrone P, Elia M, Waring RH, Romano C, ‘Sulphation deficit in “low-functioning” autistic children: a pilot study’, Biol Psychiatry 1999 Aug 1; 46(3):420-424
Altman DG, Bland JM, ‘Absence of evidence is not evidence of absence’, Br Med J, 1995;311:485
American Academy of Pediatrics and US Public Health Service, July 8, 1999, 'Thimerosal, a Mercury-containing Preservative Used in Some Vaccines'
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington D.C., 1994
Amin-Zaki L, Majeed MA, Clarkson TW, Greenwood MR, ‘Methylmercury poisoning in Iraqi children: clinical observations over two years’, British Medical Journal 1978 March 1, 613-616
Amin-Zaki L, Majeed MA, Elhassani SB, Clarkson TW, Greenwood MR, Doherty RA, ‘Prenatal Methylmercury Poisoning’, American Journal of the Disabled Child, 1979 Feb 133:172-177
Amin-Zaki, L, Elhassani S, Majeed MA, Clarkson TW, Doherty RA, Greenwood M, ‘Intra-uterine methylmercury poisoning in Iraq’, Pediatrics 1974 Nov 54:5587-595
Anuradha B, Rajeswari M, Varalakshmi P, ‘Degree of peroxidative status in neuronal tissues by different routes of inorganic mercury administration’, Drug Chem Toxicol 1998 Feb;21(2):47-55
Applied Toxicology, 1992 Apr;12(2):79-84
ARI Newsletter, review, 'Long term follow-up: early intervention effects lasting', 1993 7(1):1&6
Aronow R, Fleischmann L ,‘Mercury Poisoning in Children’, Clinical Pediatrics, 1976 Oct, Vol.15, No.10, 936-945
Arvidsson T, Danielsson B, Forsberg P, Gillberg C, Johansson M, Kjellgren G, ‘ Autism in 3-6 year old children in a suburb in Göteborg, Sweden’, Autism, November 1997, Vol. 1, No. 2, 163-173
Aschner M, Aschner JL, ‘Mercury Neurotoxicity: Mechanisms of Blood-Brain Barrier Transport’, Neuroscience & Behavioral Reviews, 1990, Vol. 14, 169-176
Aschner M, Lorscheider FL, Cowan KS, Conklin DR, Vimy MJ, Lash LH, ‘Methallothionein induction in fetal rat brain and neonatal primary astrocyte cultures by in utero’, Brain Res, Dec 5; 778(1):222-232
Ashour H, Abdel-Rahman M, Khodair A., 1993 ‘The mechanism of methyl mercury toxicity in isolated rat hepatocytes’, Toxicology Letters 1993 Jul;69(1):87-96
Atchison WD and Hare MF, ‘Mechanisms of methylmercury-induced neurotoxicity’, FASEB Journal 1994 Jun;8(9):622-629
Atchison WD, Joshi U, Thornburg JE, ‘Irreversible Suppression of Calcium Entry into Nerve Terminals by Methylmercury’, The Journal of Pharmacology and Experimental Therapeutics, 1986, Vol. 238, No. 2, 618-624
Aukrust P, et al, ‘Decreased levels of total and reduced glutathione in CD4+ lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress’, Blood, 1995, 86.4.1383-1391
Aukrust P, et al, 'Persistent activation of the tumor necrosis factor system in subgroup of patients with common variable immunodeficiency - possible immunological and clinical consequences’, Blood, 1996, 97.2.674-681
Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, Barta PE, Pearlson GD, 'MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults', Neurology 1999 Dec 10;53(9):2145-50
Bachevalier J, 'Brief Report: Medial Temporal Lobe and Autism: A Putative Animal Model in Primates', Journal of Autism and Developmental Disorders, 1996;26(2):217-220
Bachevalier J, 'Medial Temporal Lobe Structures: a Review of Clinical and Experimental Findings', Neuropsychologia, 1994;32:627-648
Bagenstose LM, Salgame P, Monestier M, ‘Mercury-induced autoimmunity in the absence of IL-4’, Clin Exp Immunol, Oct 1998, 114(1):9-12
Bagenstose LM, Salgame P, Monestier M, ‘Murine mercury-induced autoimmunity: a model of chemically related autoimmunity in humans’, Immunol Res, 1999, 20(1):67-78
Bailey A, Phillips W, Rutter M, ‘Autism: Towards an Integration of Clinical, Genetic, Neuro-psychological, and Neurobiological Perspectives’, J Child Psychol Psychiatry 1996 Jan; 37(1): 89-126.
Bailey A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, Rutter M, Lantos, 'A clinicopathological study of autism', Brain 1998 May;121 ( Pt 5):889-905
Bakir F, Damluji  SF, Amin-Zaki L, Murtadha M, Khalidi A, Al-Rawi NY, Tikrit S, Dhahir HI, Clarkson TW, Smith JC, Doherty RA, ‘Methylmercury poisoning in Iraq’, Science, July 1973, 181;230-241
Baranek G, 'Autism During Infancy:  A Retrospective Video Analysis of Sensory-Motor and Social Behaviors and 9-12 Months of Age', Journal of Autism and Developmental Disorders, 1999, Vol. 29, No. 3, pp. 213-224
Baron-Cohen S, Ring HA, Wheelwright S, Bullmore ET, Brammer MJ, Simmons A, Williams SC, 'Social intelligence in the normal and autistic brain: an fMRI study', Eur J Neuroscience 1999 Jun;11(6):1891-8
Baron-Cohen S, Leslie A, Frith U, ‘Does the autistic child have a ‘theory of mind’?’, Cognition, 1985, No. 21, pp. 37-46
Baron-Cohen S, Allen J, Gillberg C, 'Can autism be detected at 18 months: the needle, the haystack, and the CHAT', Br. J. Psychiatry, 1992;161:839-843
Baron-Cohen S, Tager-Flusberg H, Cohen D, Understanding Other Minds: Perspectives from Autism, Oxford: Oxford University Press, 1993
Barregard L, Sallsten G, Conradi N, ‘Tissue levels of mercury determined in a deceased worker after occupational exposure’, Int Arch Occup Environ Health 1999 May;72(3):169-173
Bartolome J, Whitmore WL, Seidler FJ, Slotkin TA 1984 ‘Exposure to methylmercury in utero: effects on biochemical development of catecholamine neurotransmitter systems’, Life Sciences 1984 Aug 6;35(6):657-670
Bauman ML, Kemper TL, 'Neuroanatomical observations of the brain in autism', in Bauman & Kemper, eds, The Neuroanatomy of Autism, The Johns Hopkins University Press
Bauman ML and Kemper TL, Journal of Experimental Neurology, 1988 47:369
Bauman M, Kemper TL, 'Histoanatomic observations of the brain in early infantile autism', Neurology, 1985;35:866-874
Bernabei P, Camaioni L, Levi G, ‘An evaluation of early development in children with autism and pervasive developmental disorders from home movies: preliminary findings’, Autism, September 1999, Vol. 2, No. 3, 243-258
Bettleheim B, 'A letter from Bruno Bettleheim', Autism Research Review International, 1989,  Vol 3,  No. 3, p. 6
Bidet B, Leboyer M, Descours B, Bouvard MP, Benveniste J, ‘Allergic sensitization in infantile autism’ (letter), Journal of Autism and Developmental Disorders, June 1993, Vol. 23, No. 2, pp. 419-420
Binstock T, 'Fragile X and the amygdala: cognitive, interpersonal, emotional, and neuroendocrine considerations', Dev Brain Dysfunction 1995 8:199-217
Bonnet JJ, Benmansour S, Amejdki-Chab N, Costentin J, ‘Effect of CH3HgCl and several transition metals on the dopamine neuronal carrier; peculiar behaviour of Zn2+’, Eur J Pharmacol 1994 Jan 1;266(1)87-97
Bouilleret V, Boyet S, Marescaux C, Nehlig A, ‘Mappingof the progressive metabolic changes occurring during the development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy’, Brain Research, 2000, 952:255-262
Brenner RP and Snyder RD, ‘Late EEG finding and clinical status after organic mercury poisoning’, Archives of Neurology 1980 May; 37(5):282-284
Bristol M, Cohen D, Costello E, Denckla M, Eckberg T, Kallen R, Kraemer H, Lord C, Maurer R, McIlvane W, Minshew N, Sigman M, Spence M, 'State of the Science in Autism: Report to the National Institutes of Health' , Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, pp. 121-157
Bryson SE, ‘Brief Report: Epidemiology of Autism’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 165-167
Bryson SE, Smith IM, Eastwood D, 'Obstetrical suboptimality in autistic children', J Am Acad Child Adolesc Psychi, 1988;27(4)418-22
Bulleit RF, Cui H, ‘Methylmercury antagonizes the survival-promoting activity of insulin-like growth factor on developing cerebellar granule neurons’, Toxicol Appl Pharmacol 1998 Dec;153(2):161-168.
Cagiano R, De Salvia MA, Renna G, Tortella E, Braghiroli D, Parenti C, Zanolie P, Baraldi M, Annau Z, Cuomo V, ‘Evidence that exposure to methyl mercury during gestation induces behavioral and neurochemical changes in offspring of rats’, Neurotoxicol Teratol 1990 Jan-Feb;12(1):23-28
Camerino , Cassitto M, 'Behavior of Some Psychological Parameters of a Population of a Hg Extraction Plant', Journal of Clinical Toxicology, 1981, Vol. 18 (11), pp. 1299-1309
Capps L, Kehres J, Sigman M, 'Conversational abilities among children with autism and children with developmental delays', Autism, 1998 Dec;2(4):325-44
Carlsson ML, ‘Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy’, Journal of Neural Transmitters 1998 105(4-5):525-535
Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N, ‘The 5-HT2A receptor antagonis M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice’, J Neural Transm 1999; 106(2):123-129
Carpenter PK, Morris D, ‘Association of acrocyanosis with Asperger’s syndrome’, Journal of Mental Deficiency Research, 1990, 34, pp. 97-90
CDC, ‘Recommendations Regarding the Use of Vaccines That Contain Thimerosal as a Preservative’, MMWR November 5, 1999 / 48(43); 996-998
CDC, ‘Thimerosal in vaccines: a joint statement of the Amercian Academy of Pediatrics and the Public Health Service’, MMWR Morb Mortal Wkly Rep 1999 July 9; 48(26):563-565
CDC, 'Record Immunization Rate, 80% of Kids Getting Vaccinated', Associated Press, September 23, 1999
Cesaroni L, Garber M, 'Exploring the experience of autism through firsthand accounts', Journal of Autism and Developmental Disorders, 1991 Sep;21(3):303-13
Chapman AG, Elwes RD, Millan MH, Polkey CE, Meldrum BS, 'Role of Glutamate and Aspartate in Epileptogenesis; Contribution of Microdialysis Studies in Animal and Man', Epilepsy Res Suppl, 1996, Vol. 12, pp. 239-246
Cheek DB, 'Acrodynia', in Brennemann's Practice of Pediatrics, Chapter 17D, from Pink Disease website, www.users.bigpond.com/difarnsworth/pcheek42.htm
Chodorowski Z, Sein Anand J, Nowicki A, Galant K, ‘Subcutaneous self-injection and oral self-administration of metallic mercury - case report’, Przegl Lek 1997;54(10):759-762
Chu CC, Huang CC, Ryu SJ, Wu TN, ‘Chronic inorganic mercury induced peripheral neuropathy’, Acta Neurology Scandanavia 1998 Dec;98(6):461-465
Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT, ‘Developmental Changes in Brain Serotonin Synthesis Capacity in Autistic and Nonautistic Children’, Ann Neurol 1999; 45:
Church C, Coplan J, 'The High Functioning Autistic Experience: Birth to Preteen Years', Journal of Pediatric Health Care, 1995, Vol. 9, pp.22-29
Clarke D, Baxter M, Perry D, Prasher V, 'The diagnosis of affective and psychotic disorders in adults with autism: seven case reports', Autism, 1999 Jun;3(2):149-164
Clarkson TW, ‘Mercury: Major Issues in Environmental Health’, Environmental Health Perspectives vol. 100, pp. 31-38, 1992
Clarkson, T. 1997 ‘The Toxicology of Mercury’, Critical Reviews in Clinical Laboratory Sciences, 34(3): 369-403 (1997)
Clarkson, TW, ‘Mercury - an element of mystery’, The New England Journal of Medicine 1990 Oct 18
Clarkson,T.W, 1993, 'Molecular and ionic mimicry of toxic metals', Annu. Rev. Pharmacol. Toxicol. 32:545-571
Cloarec S, Deschenes G, Sagnier M, Rolland JC, Nivet H, ‘Arterial hypertension due to mercury poisoning: diagnostic value of captopril’, Arch Pediatr 1995 Jan;2(1):43-46
Close AH, Guo TL, Shenker BJ, ‘Activated human T lymphocytes exhibit reduced susceptibility to methylmercury chloride-induced apoptosis’, Toxicol Sci 1999 May;49(1):68-77
Coccini T, Randine G, Candura SM, Nappi RE, Prockop LD, Manzo L, ‘Low-Level Exposure to Methylmercury Modifies Muscarinic Cholinergic Receptor Binding Characteristics inRat Brain and Lymphocytes: Physiologic Implications and New Opportunities in Biologic Monitoring’, Environ Health Perspect, 2000 Jan;108(1):29-33
Coleman M, ‘Nutritional treatments currently under investigation in autism’, Clinical Nutrition, Sept/Oct 1989, Vol. 8, No. 5, pp. 210-212
Comi AM, Zimmerman A et al, 'Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism', Journal of Child Neurology, 1999, Vol. 14, pp. 388-394
Connolly AM, et al, ‘Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders’, Journal of Pediatrics, May 1999, Vol. 134, No. 5, pp. 607-613
Cook EH, ‘Autism: review of neurochemical investigation’, Synapse, 1990, 6:292-308
Courchesne E, et al,‘More evidence links autism, cerebellar defects’, reviewed in Autism Research Review International, 1994, Vol. 8, No. 2, pp. 1&7
Courchesna E, Press GA, Young-Courchesne R, 'Parietal lobe abnormalities detected with MR in patients with infantile autism', AJR Am J Roentgenol 1993 Feb;160(2):387-93
Courchesne E, 'Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism', Current Opin Neurobiol 1997 Apr;7(2):269-78
Courchesne E, Saitoh O, Townsend J, Yeung-Courchesne R, Lincoln AJ, Schreibman L, Haas RH, Press GA, 'Cerebellar Abnormalities in Autism: New Evidence and A Re-Analysis of Old Evidence', pp. 211-214
Courchesne E, Yeung-Courchesne R, Elmasian R, Grillon C, 'Pathophysiologic findings in non-retarded autism and receptive developmental language disorder', Journal of Autism and Developmental Disorders, 1989; 19:1-17
Courchesne E, Yeung-Courchesne R, Press GA, Hesselink JR, Jernigan TL, ‘Hypoplasia of cerebellar vermal lobules VI and VII in autism’, New England Journal of Medicine 1988 318:1349-1354
Courchesne E, Yeung-Courchesne R, Press GA, Hesselink JR, Jernigan TL, ‘Hypoplasia of cerebellar vermal lobules VI and VII in autism’, New England Journal of Medicine, May 26, 1998; pp. 1349-1354
Courchesne E, reported in The New York Times, 'Science Times' section, Dec 28, 1999, by Blakeslee S
Cox NH, Forsyth A, ‘Thiomersal allergy and vaccination reactions’, Contact Dermatitis 1988:18:229-233
Creel DJ, Crandall AS, Pingree C, Ritvo ER, 'Abnormal electroretinograms in autism', Clinical Vision Science 1989 4(1):85-88
Cuomo V, Ambrosi L, Annau Z, Cagiano R, Brunello N, Racagni G 1984, ‘Behavioral and neurochemical changes in offspring of rats exposed to methyl mercury during gestation’, Neurobehavior Toxicology Teratol 1984 May-June;6(3):249-254
D’Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O, ‘Abnormal intestinal permeability in children with autism’, Acta Pædiatr 1996:85:1076-1079
D’Eufemia P, Finocchiaro R, Celli M, Viozzi L, Monteleone D, Giardini O, ‘Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism’, Biomed. & Pharmacother., 1995, Vol. 49, pp. 288-292
Dales LD, ‘The Neurotoxicity of Alkyl Mercury Compounds’, American journal of Medicine, August 1972, Vol. 53, 219-232
Dally A, 'The Rise and Fall of Pink Disease', Wellcome Institute for the History of Medicine, 1997, available at www.users.bigpond.com/difarnsworth
Dathan JG, 'Pink Disease-Ten Years After (The Epilogue), British Medical Journal, 1965, Vol 1, pp. 1181-1182
Dave V, Mullaney KJ, Goderie S, Kimelberg HK, Aschner M, ‘Astrocytes as mediators of methylmercury neurotoxicity: effects on D-aspartate and serotonin uptake’, Dev Neurosci 1994;16(3-4):222-231
Davis LE, Kornfeld M, Mooney HS, Fiedler KJ, Haaland KY, Orrison WW, Cernichiari E, Clarkson TW, ‘Methylmercury poisoning: long term clinical, radiological, toxicological, and pathological studies of an affected family’, Annals of Neurology 1994 35:6 680-688
Dawson G, ‘Brief Report: Neuropsychology of Autism: A Report on the State of the Science’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 179-184
Deb S and Thompson B, ‘Neuroimaging in autism’, British Journal of Psychiatry 1998 Oct 173:299-302
DelGiuidce-Asch G, Hollander E, ‘Altered immune function in autism’, CNS Spectrums: International Journal of Neuropsychiatric Medicine, 1997, 2:61-68
DeLong GR, ‘Autism: new data suggest a new hypothesis’, Neurology, March 1999, Vol. 52, No. 5, pp. 911-916
Deutsch S, Campbell M, Sachar E, Green W, David R, ‘Plasma growth hormone response to oral L-dopa in infantile autism’, Journal of Autism and Developmental Disorders, June 1985, Vol. 15, No. 2, pp. 205-212
Deyab P, Gochfeldbc M, Reuhlabca K, 'Developmental Methylmercury Administration Alters Cerebellar PSA-NCAM expression and Golgi sialyltransferase Activity', 1999
Diner Barry, M.D., Brenner Barry, M.D.,Toxicity, Mercury, 1998
Edelson MG, Edelson SM, Jung S, ‘Assessing the Intelligence of Individuals with Autism: A Cross-Cultural Replication of the Usefulness of the TONI’, Focus on Autism and Other Developmental Disabilities, Winter 1998, Vol. 13, No. 4, 221-227
Edelson MG, Schubert DT, Edelson SM, ‘Factors Predicting Intelligence Scores on the TONI in Individuals with Autism’, Focus on Autism and Other Developmental Disabilities, Spring 1998, Vol. 13, No. 1, 17-26
Edelson SB, Cantor DS, ‘Autism: xenobiotic influences’, Toxicol Ind Health, 1998 Jul-Aug;14(4):553-563
Egan, William M. 1999 ‘Thimerosal in Vaccines’, presentation to the FDA, September 14, 1999
Eisenmayer R et al, 'Delayed language onset as a predictor of clinical symptoms in pervasive developmental disorders', Journal of Autism and Developmental Disorders, 1998 Dec 28(6):527-33
El-Fawal HA, Waterman SJ, De Feo A, Shamy MY, ‘Neuroimmunotoxicology: Humoral Assessment of Neurotoxicity and Autoimmune Mechanisms’, Environ Health Perspect 1999 Oct;107(Suppl 5):767-775
Elferink JG Thimerosal: a versatile sulfhydryl reagent,calcium mobilizer, and cell function-modulating agent.Gen Pharmacol 1999 Jul;33(1):1-6
Environmental Protection Agency (EPA), lead authors - Hassett-Sipple B, Swartout J, Schoeny R, 'Vol. V - Health Effects of Mercury and Mercury Compounds', Mercury Study Report to Congress, December 1997
Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Cohen RM, 'Low medial prefrontal dopaminergic activity in autistic children', Lancet 1997 Aug 30;350(9078):638
Eto K, Takizawa Y, Akagi H, Haraguchi K, Asano S, Takahata N, Tokunaga H, ‘Differential diagnosis between organic and inorganic mercury poisoning in human cases - the pathologic point of view’, Toxicol Pathol 1999 Nov-Dec;27(6):664-671
Fagala GE,Wigg CL, ‘Psychiatric Manifestions of Mercury Poisoning’, J. Am. Acad. Child. Adolesc. Psychiatry, March 1992,  31(2):306-311.
Fagan DG, Pritchard JS, Clarkson TW, Greenwood MR, ‘Organ mercury levels in infants with omphaloceles treated with organic mercurial antiseptic’, Archives of Disease in Childhood, 1977 52:962-964
Farnsworth D, ‘Pink Disease Survey Results’, Pink Disease Support Group Site, 1997 www.users.bigpond.com/difarnsworth
Faro LR, Duran R, do Nascimento JL, Alfonso M, Picanco-Diniz CW, ‘Effects of methyl mercury on the in vivo release of dopamine and its acidic metabolites DOPAC and HVA from Striatum of rats’, Ecotoxicol Environ Saf 1997 Nov;38(2):95-98
Faro LRF, Nascimento JLM do, Alfonso M, Duran R, ‘Acute Administration of Methylmercury Changes In Vivo Dopamine Release from Rat Striatum’, Bulletin of Environmental Contamination Toxicology, 1998 60:632-638
FDA, HHS, ‘Mercury Containing Drug Products for Topical Antimicrobial Over-the-Counter Human Use; Establishment of a Monograph’, Federal Register, January 5 1982, Vol. 47, No. 2, 436-442
FDA, 'Mercury Compounds in Drugs and Food', 98N-1109, November 16, 1999
Feldman R, 'Neurological Manifestations of Mercury Intoxication', Journal of Occupational Neurology, 1982, Vol. 66, pp. 201-209
Filipek P, Accardo P, Baranek G, Cook E, Dawson G, Gordon B, Gravel J, Johnson C, Kallen R, Levy S, Minshew N, Prizant B, Rapin I, Rogers S, Stone W, Teplin S, Tuchman R, Volkmar F, 'The Screening and Diagnosis of Autistic Spectrum Disorders', Journal of Autism and Developmental Disorders, 1999, Vol. 29, No. 6, pp. 439-484
Finegan J, Quarrington B, 'Pre-, peri-, and neonatal factors and infantile autism', J Child Psychol Psychi, 1979; 20.119-128
Florentine MJ and Sanfilippo II DJ, ‘Grand Rounds: Elemental mercury poisoning’, Clinical Pharmacy 1991 Mar 10:213-221
Fombonne E, Rogé B, Claverie J, Courty S, Frémolle J, ‘Microcephaly and Macrocephaly in Autism’ Journal of Autism and Developmental Disorders, 1999, Vol. 29, No. 2, 113-119
Food and Drug Administration, 1997 ‘Status of Certain Additional Over-the-Counter Drug Category II and III Active Ingredients’, Docket Nos. 75N-183F, 75N-183D, and 80N-0280, October 19,1998
Fournier L, Thomas, G, Garnier, R, Buisine, A, Houze, P, Pradier, F, and Dally, S 1988, ‘2,3-Dimercaptosuccinic Acid Treatment of Heavy Metal Poisoninig in Humans’, Medical Toxicology 3: 499-505 (1988)
Frackelton JP, Christensen RL, ‘Mercury Poisoning and Its Potential Impact on Hormone Regulation and Aging: Preliminary Clinical Observations Using a New Therapeutic Approach’, Journal of Advancement in Medicine 1998 Spring 11(1):9-25
Fredriksson A, Dencker L, Archer T, Danielsson BGR, ''Prenatal coexposure to metallic mercury vapour and methylmercury produce interactive behavioural changes in adult rats', Neurotoxicol Teratol 1996 19(2):129-134
Fuchs J, Packer L, Zimmer G, Lipoic Acid in Health and Disease, Marcel Dekker, Inc., 1997
Fuchs J, Schöfer H, ‘Redox Modulation of Signal Transduction and Gene Expression in HIV Infection: The Role of the Antioxidant Lipoate’, Lipoic Acid in Health and Disease, Fuchs, Packer, & Zimmer (eds), Marcel Dekker, Inc., 1997, 435-454
Fudenberg HH, ‘Dialysable Lymphocyte Extract (DLyE) in Infantile Onset Autism: A Pilot Study’, Biotherapy (1996) 9:143-147
Fukino H, Hirai M, Hsueh YM, Yamane Y,‘Effect of zinc pretreatment on mercuric chloride-induced lipid peroxidation in the rat kidney’, Toxicol Appl Pharmacol 1984 May;73(3):395-401
Gaffney GR, Kuperman S, Tsai LY, Minchin S, ‘Morphological evidence for brainstem involvement in infantile autism’, Biological Psychiatry, September 1988, 24:578-586
Gilbert SG, Grant-Webster KS, ‘Neurobehavioral effects of developmental methymercury exposure’, Environmental Health Perspectives, 1995 Sept; 103 Suppl 6:135-142
Gillberg C, Coleman M, The Biology of the Autistic Syndromes - 2nd Edition, Mac Keith Press, 1992
Gillberg C, Dev Med Child Neurol 37, 23-45 (1995)
Gillberg C, Gillberg IC, 'Infantile Autism: a total population study of reduced optimality in the pre-, peri- and neonatal period', Journal of Autism and Developmental Disorders, 1983, Vol 13, No. 2, pp. 153-166
Gillberg C, Svennerholm L, ‘CSF monoamines in autistic syndromes and other pervasive dev. disorders of early childhood’, British Jour. of Psychiatry, 1987, No. 151, pp. 89-94
Gillberg C, Wing L, ‘Autism: not an extremely rare disorder’, Acta Psychiatr Scand 1999 Jun;99(6)399-406
Goldberg M, Mena I, Miller B, ‘Frontal and temporal lobe dysfunction in autism and other related disorders: ADHD and OCD’, Latin American Journal of Nuclear Medicine, July 1999, available online: http://www.alabimnjournal.cl
Golse B, Debray-Ritzen P, Durosay P, Puget K, Michelson AM, ‘Alterations in two enzymes: superoxide dismutase and glutathion peroxidase in developmental infantile psychosis’, Revue Neurologic (Paris) 1978 Nov;134(11):699-705
Gosselin RE, Smith RP, Hodge HC, Clinical Toxicology of Commercial Products, Section III, Therapeutic Index, 'Mercury',  (5th edition),  Baltimore, Williams & Wilkins, 1984: pp262-271.
Grandin T, ‘Brief Report: Response to National Institutes of Health Report’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 185-187
Grandin T, ‘The Learning Style of People With Autism: An Autobiography’, Teaching Children with Autism, Kathleen Ann Quill, 33-52
Grandjean P, Budtz-Jorgensen E, White RF, Jorgensen PJ, Weihe P, Debes F, Keiding N, ‘Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years’, Am J Epidemiol 1999 Aug 1; 150(3):301-305
Grandjean P, Guldager B, Larsen IB, Jergensen PJ, Holmstrup P, ‘Placebo Response in Environmental Disease’, JOEM 1997 August, Vol. 38, No. 8,707-714
Grandjean P, Weihe P, White RF, Debes F, ‘Cognitive performance of children prenatally exposed to “safe” levels of methylmercury’, Environmental Research 1998 May; 77(2): 165-172
Grandjean P, White RF, Nielsen A, Cleary D, de Oliveira Santos EC, ‘Methylmercury neurotoxicity in Amazonian children downstream from gold mining’, Environ Health Perspect 1999 Jul;107(7):587-591
Grundt IK, Stensland E, Syverson TL, ‘Changes in fatty acid composition of myelin cerebrosides after treatment of the developing rat with methylmercury chloride and diethylmercury’. J Lipid Res, 1980 Feb;21(2):162-168
Gunderson, VM, Grant KS, Burbacher TM, Fagan 3rd JF, Mottet, NK, ‘The effect of low-level prenatal methyl mercury exposure on visual recognition memory in infant’, Child Dev., 1986, 57(4):1076-1083
Gunderson, VM, Grant KS, Burbacher TM, et al, ‘Visual recognition memory deficits in methyl mercury exposed Macaca fascicularis infants’, Neurotoxicol Teratol., 1988, 10(4):373-379
Gupta S, Aggarwal S, Heads C, ‘Brief Report: Dysregulated Immune System in Children with Autism: Beneficial Effects of Intravenous Immun Globulin on Autistic Characteristics’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 4, 439-452
Gupta S, Aggarwal S, Rashanravan B, Lee T, ‘Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism’, J Neuroimmunol 1998 May 1;85(1):106-109
Haeney MR, Carter GF, Yeoman WB, Thompson RA, ‘Long-term parental exposure to mercury in patients with hypogammaglobulinaemia’, British Medical Journal 1979 2:12-14
Hagerman RJ, 'Possible similarities between the fragile X and Asperger syndrome', American Journal of Diseases of Children, 1987;141:601-602
Halsey NA, 'Perspective on the use of thimerosal-containing vaccines', presentation at the National Vaccine Advisory Committee Workshop on Thimerosal and Vaccines, August 11-12, 1999, available on  Institute of Vaccine Safety website, www.vaccinesafety.edu
Halsey NA, ‘Limiting Infant Exposure to Thimerosal in Vaccines and Other Sources of Mercury’, JAMA, November 10, 1999, Vol. 282, No. 18
Hartman DE, 'Missed diagnoses and misdiagnoses of environmental toxicant exposure', Diagnostic Dilemmas, Part I, 1998 Sep;21(3):659-671
Hashimoto T, Tayama M, Miyazaki M, Sakurama N, Yoshimoto T, Murakawa K, Kuroda Y, ‘Reduced brainstem size in children with autism’, Brain & Development, 1992, Vol. 14, No. 2, pp. 94-97
Hashimoto T, Tayama M, Murakawa K, Yoshimoto T, Miyazaki M, Harada M, Kuroda Y, ‘Development of the brainstem and cerebellum in autistic patients’, Journal of Autism and Developmental Disorders, 1995, Vol. 25, No. 1, pp. 1-18
Haznedar MM, Buchsbaum MS, Metzger M, Solimando A, Spiegel-Cohen J, Hollander E, ‘Anterior Cingulate Gyrus Volume and Glucose Metabolism in Autistic Disorder’, Amercian Journal of Psychiatry 1997 Aug 154(8):1047-1050
Hepatitis Control Report, ‘Uproar over a little-known preservative, thimerosal, jostles U.S. hepatitis B vaccination policy’, Summer 1999, Vol. 4, No. 2
Hollander E, Kaplan A, Cartwright C, Reichman D, ‘Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report’, J Child Neurol, 2000, Feb;15(2):132-135
Hoon AH and Riess AL, ‘The mesial-temporal lobe and autism: case report and review’, Developmental Medicine and Child Neurology 1992 34:252-265
Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT, ‘Gastrointestinal abnormalities in children with autistic disorder’, Journal of Pediatrics 1999 Nov 135(5):559-563
Hoshino Y, Watanabe M, Kumashiro H, ‘The hypothalamo-pituitary function in autistic children: the change of serum 5HT, plasma human growth hormone, prolactin level after L-5HTP loading’, Neurosciences, 1984, Vol. 10, pp. 285-291
Hoshino Y, Watanabe M, Kumashiro H, ‘The TRH and LH-RH loading test in autistic children’, Journal of Medical Science, 1985, Vol. 31, No. 1
Howlin P, 'Outcome in adult life for more able individuals with autism or Asperger syndrome', Autism 2000 Mar;4(1):63-84
Hrdina PD, Peters DA, Singhal RL 1976, ‘Effects of chronic exposure to cadmium, lead and mercury of brain biogenic amines in the rat’, Research Communications in Chemistry, Pathology and Pharacology 1976 Nov;15(3):483-493
Hu H, Abedi-Valugerdi M, Moller G, ‘Pretreatmet of lymphocytes with mercury in vitro induces a response in T cells from genetically determine low-responders and a shift of the interleukin profile’, Immunology, 1997 90:198-204
Hu H, Möller G, Abedi-Valugerdi M, ‘Major histocompatibility complex class II antigens are required for both cytokine production and proliferation induced by mercuric chloride in vitro’, J Autoimmun, Oct 1997, 10(5):441-446
Hu H, Moller G, Abedi-Valugerdi M, ‘Mechanism of mercury-induced autoimmunity: both T helper 1- and T helper 2-type responses are involved’, Immunology, March 1999, 96(3):348-357
Hua MS, Huang CC, Yang YJ, 'Chronic elemental mercury intoxication: neuropsychological follow up case study', Brain Inj 1996 May;10(5):377-84
Hultman P, Hansson-Georgiadis H, ‘Methyl mercury-induced autoimmunity in mice’, Toxicol Appl Pharmacol, Feb 1, 1999, 154(3):203-211
Hultman P, Nielsen JB, ‘The effect of toxicokinetics on murine mercury-induced automimunity’, Environ Res, May 1998, 77(2):141-148
Hultman P, Turley SJ, Eneström S, Lindh U, Pollard KM, ‘Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity’, J Autoimmun, April 1996, 9(2): 139-149
Hussain S, Atkinson A, Thompson SJ, Khan AT, ‘Accumulation of mercury and its effect on antioxidant enzymes in brain, liver, and kidneys of mice’, J Environ Sci Health B 1999 Jul;34(4):645-660
Ikeda M, Komachi H, Sato I, Himi T, Yuasa T, Murota S, ‘Induction of neuronal nitric oxide synthase by methylmercury in the cerebellum’, Journal of Neuroscience Research 1999 Feb 1;55(3):352-356.
Ikeda M, Komachi H, Sato I, Himi T, Yuasa T, Murota S, ‘Induction of neuronal nitric oxide synthase by methylmercury in the cerebellum’, J Neurosci Res 1999 Feb 1;55(3):352-356
Ilback NG, ‘Effects of methyl mercury exposure on spleen and blood natural-killer (NK) cell-activity in the mouse’, Toxicology, 1991, 67(1):117-124
Islam MS, Berggren PO, Larsson O, ‘Sulfhydryl oxidation induces rapid and reversible closure of the ATP-regulated K+ channel in the pancreatic beta cell’, FEBS Lett 1993 Mar 15;319(1-2):128-132
Jaffe JS, et al, ‘Functional abnormalities of CD8+ t cells define a unique subset of patients with common variable immunodeficiency’, Blood, 1993, 82.1.192-2001
Jaselskis C, Cook E, Fletcher K, and Bennett L, ‘Clonidine treatment of hyperactive and impulsive children with autistic disorder’, Journal of Clinical Psychopharmacology 1992
Johansson U, Hansson-Georgiadis H, Hultman P, ‘The genotype determines the B cell response in mercury-treated mice’, Int Arch Allergy Immunol, Aug 1998, 116(4):295-305
Joselow MM, Louria DB, Browder AA, ‘Mercurialism: Environmental and Occupational Aspects’, Annals of Internal Medicine 1972 76:119-130
Joseph SK, Ryan SV, Pierson S, Renard-Rooney D, Thomas AP, ‘The effect of mersalyl on inositol trisphosphate receptor binding and ion channel function’, J Biol Chem 1995 Feb 24;270(8):3588-3593
Journal of Autism and Developmental Disorders, 1995, Vol. 25, No. 2
Kabuto M,‘Chronic effects of methylmercury on the urinary excretion of catecholamines and their responses to hypoglycemic stress’, Arch Toxical 1991;65(2):164-167
Kanner L, ‘Autistic Disturbances of Affective Contact’, The Nervous Child 1942-1943, Vol. 2, No. 3, 217-250
Karhapaa l, Titievsky A, Kaila K, Tornquist K, ‘Redox modulation of calcium entry and release of intracellular calcium by thimerosal in GH4C1 pituitary cells’, Cell Calcium 1996 Dec;20(6):447-457
Kark RA, Poskanzer DC, Bullock JD, Boylen G. ‘Mercury poisoning and its treatment with N-acetyl-D, L-penicillamine’, New England Journal of Medicine 1971;285:10-16
Kates WR, Mostofsky SH, Zimmerman AW, Mazzocco MM, Landa R, Warsofsky IS, Kaufmann WE, Reiss AL, ‘Neuroanatomical and neurocognitive differences in a pair of monozygous twins discordant for strictly defined autism’, Ann Neurol 1998 Jun; 43(6):782-791
Kinoshita Y, Ohnishi A, Kohshi K, Yokota A, ‘Apparent diffusion coefficient on rat brains and nerves intoxicated with methylmercury’, Environ Res 1999 May;80(4):348-354.
Klin A, Sparrow SS, de Bildt A, Cicchetti DV, Cohen DJ, Volkmar FR, 'A Normed Study of Face Recognition in Autism and Related Disorders', Journal of Autism and Developmental Disorders December 1999 29:6 499-508
Koegel LK, Koegel RL, Smith A, ‘Variables Related to Differences in Standardized Test Outcomes For Children with Autism’, Journal of Autism and Developmental Disorders, 1997, Vol. 27, No. 3, 233-243
Koos BJ and Longo LD, ‘Mercury toxicity in the pregnant woman, fetus, and newborn infant’, American Journal of Obstetrics and Gynecology 1976 Oct 126(3):390-406
Kugler B, 'The differentiation between autism and Asperger syndrome', Autism, 1998 Mar;2(1):11-32
Kurita H, ‘Infantile autism with speech loss before the age of thirty months’, Journal of the American Academy of Child Psychiatry, 1985, Vol. 24, Issue 2, pp. 191-196
LaCamera RG, LaCamera AC, 'Routine Health Care', Handbook of Autism and Pervasive Developmental Disorders, Cohen D, Donnellan AM, Paul R, eds, 1987 by John Wiley & Sons, Inc., p584-595
Larkfors L, Oskarsson A, Sundberg J, Ebendal T, ‘Methylmercury induced alterrations in the nerve growth factor level in the developing brain’, Brain Res Dev Brain Res 1991 Oct 21; 62(2) 287-291
Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F, Feingold J, Mouren-Simeoni MC, Launay JM, 'Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives', Biol Psychiatry 1999 Jan 15;45(2):158-63
Lewine 'Magnetoenchalography in Children with an Autistic Epileptiform Regression', J Pediatrics, 1999 405-418
Lewis MH, ‘Brief Report: Psychopharmacology of Autism Spectrum Disorders’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 231-235
Li S, Thompson SA, Woods JS, ‘Localization of gamma-glutamylcysteine synthetase mRNA expression in mouse brain following methylmercury treatment using reverse transcription in situ PCR amplification’, Toxicol Appl Pharmacol, Sept 1996, 140(1):180-187
Lombard J, ‘Autism: a mitochondrial disorder?’, Medical Hypotheses 1998 Jun;50(6):497-500
Lorscheider FL, Vimy MJ, Summers AO, ‘Mercury exposure from “silver” tooth fillings: emerging evidence questions a traditional dental paradigm’, The FASEB Journal, April 1995, Vol. 9, 504-508
Lowell JA, Burgess S, Shenoy S, Curci JA, Peters M, Howard TK, ‘Mercury Poisoning Associated with High-Dose Hepatitis-B Immune Globulin Administration After Liver Transplantation for Chronic Hepatitis B’, Liver Transplantation and Surgery, Nov 1996, Vol. 2, No. 6, 475-478
Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR, ‘The comparative toxicology of ethyl- and methylmercury’, Archives of Toxicology, 1985 Sep;57(4):260-267
Malhotra S, Gupta N, 'Childhood Disintegrative Disorder', Journal of Autism and Developmental Disorders Dec 1999 29;6 491-498
Markovich D, Knight D, 'Renal Na-Si Cotransporter NaSi-1 is inhibited by heavy metals', American Journal of Renal Physiology, February 1998, Vol. 274, No. 2, pp283-289
Marty MS, Atchison WD, ‘Elevations of intracellular Ca2+ as a probable contributor to decreased viability in cerebellar granule cells following acute exposre to methyl mercury’, Toxicol Appl Pharmacol 1998 May’ 150(1):98-105
Matheson DS, Clarkson TW, Gelfand EW, ‘Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin’, Journal of Pediatrics 1980;97(1):153-155.
Mathiesen T, Ellingsen DG, Kjuus H, ‘Neuropsychological effects associated with esposure to mercury vapor among former chloralkali workers’, Scand J Work Environ Health, 1999, Aug:25(4):342-350
Mattsson JR, Miller E, Alligood JP, Koering JE, Levin SG, ‘Early effects of methylmercury on the visual evoked response of the dog’, Neurotoxicology 1981 Nov;2(3):499-514
McClelland RJ, Eyre D, Watson D, Calvert J, ‘A neurophysiological study of autistic children’, Electroencephalography and Clinical Neurophysiology, Sept. 1985, Vol. 61, p. 16
McClelland RJ, Eyre DG, Watson D, Calvert GJ, Sherrard E, British Journal of Psychiatry, 1992, 160:     659-663
McDougle C, Psycholopharmacology, Handbook of Autism and Pervasive Developmental Delay, 2nd ed. New York: John Wiley and Sons, 1997;707:729
McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH, ‘Risperidone in adults with autism or pervasive developmental disorder’, Journal of Child and Adolescent Psychopharmacology, 1995, Vol. 5, No. 4, pp. 273-282
McDougle CJ, Homes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ, ‘Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study’, Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685-693
McKay SJ, Reynolds JN, Racz WJ, ‘Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H]dopamine from mouse striatal slices’, Canadian Journal of Physiology and Pharmacology 1986 Dec 64(12):1507-1514
McKeown-Eyssen GE, Ruedy J, Neims A, ‘Methyl mercury exposure in northern Quebec: II. Neurologic findings in children’, Am. J. Epidemiol., 1983, 118:470-479
Merck & Co., Inc., ‘Merck Launches Preservative-Free Hepatitis-B Vaccine’, press release, Sept 9, 1999
Messahel S, Pheasant AE, Pall H, Ahmed-Choudhury J, Sungum-Paliwal RS, Vostanis P, ‘Urinary levels of neopterin and biopterin in autism’, Neurosci Lett 1998 Jan 23;241(1):17-20
Minnema DJ, Cooper GP, Greenland RD, ‘Effects of methylmercury on neurotransmitter release from rat brain synaptosomes’, Toxicology and Applied Pharmacology 1989 Jul 99(3):510-521
Minshew NJ, ‘Brief Report: Brain Mechanisms in Autism: Functional and Structural Abnormalities’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 205-209
Moreno H, Borjas L, Arrieta A, Saez L, Prassas A, Estevez J, Bonilla E, ‘Clinical heterogeneity of the autistic syndrome: a study of 60 families’ (Spanish), Invest Clin 1992;33(1):13-31
Moreno-Fuenmayor H, Borjas L, Arrieta A, Valera V, Socorro-Candanoza L, ‘Plasma excitory amino acids in autism’, Invest Clin 1996 Jun;37(2):113-128
Muris P, Steerneman P, Merckelbach H, Holdrinet I, Meesters C, ‘Comorbid anxiety symptoms in children with pervasive developmental disorders’, Journal of Anxiety Disorders, 1998, Vol. 12, No. 4, pp. 387-393
Musiek FE, Hanlon DP, ‘Neuroaudiological effects in a case of fatal dimethylmercury poisoning’, Ear Hear 1999 Jun;20(3):271-275
Nass R, Gross A, Devinsky O, 'Autism and autistic epileptiform regression with occipital spikes',Dev Med Child Neurol 1998 Jul;40(7):453-8
‘Neville’s (a Pinkie) Recollection of Pink Disease’, Pink Disease Support Group, www.users.bigpond.com/difarnsworth
Nielsen JB and Hultman P, ‘Experimental studies on genetically determined susceptibility to mercury-induced autoimmune response’, Renal Failure 1999 21(3&4):343-348
Nishio H, Nezasa K, Hirano J, Nakata Y, ‘Effects of thimerosal, an organic sulfhydryl modifying agent, on serotonin transport activity into rabbit blood platelets’, Neurochemistry International 1996 29(4):391-396
Nordin V, Gillberg C, ‘Autism Spectrum disorders in children with physical or mental disability or both. I: Clinical and epidemiological aspects’, Dev Med Child Neurol 1996 Apr; 38(4):297-313
Nowell MA, Hackney DB, Muraki AS, Coleman M, 'Varied MR appearance of autism: fifty-three pediatric patients having the full autistic syndrome', Magn Reson Imaging 1990;8(6):811-6
O’Carroll RE, Masterton G. Dougnall N. Ebmeier KP, 1995, ‘The neuropsychiatric sequelae of mercury poisoning: The Mad Hatter’s disease revisited’, British Journal of Psychiatry 167(1):95-98 (1995)
O’Kusky JR, Boyes BE, McGeer EG, ‘Methylmercury-induced movement and postural disorders in developing rat: regional analysis of brain catecholamines and indoleamines’, Brain Research 1988 Jan 26;439(1-2):138-146
O’Neill JL, Through the Eyes of Aliens, Jessica Kingsley Publishers Ltd., 1999
O’Neill M, Jones RSP, ‘Sensory-Perceptual Abnormalities in Autism: A Case For More Research?’, Journal of Autism and Developmental Disorders, 1997, Vol. 27, No. 3, 283-293
O’Reilly BA and Waring, R, ‘Enzyme and sulfur oxidation deficiencies in autistic children with known food/chemical intolerances’, Journal of Orthomolecular Medicine 1993 4:198-200
Ono B, Sakamoto E, ‘Saccharomyces cerevisiae strains sensitive to inorganic mercury. I. Effect of tyrosene’, Curr Genet 1985;10(3):179-185
Ono B, Sakamoto E, Yamaguchi K, ‘Saccharomyces cerevisiae strains sensitive to inorganic mercury. III. Tyrosine uptake’, Curr Genet 1987;11(5):399-406
O'Reilly B,  Waring R,  'Enzyme and Sulphur Oxidation Deficienceies in Autistic Children with Known Food/Chemical Intolerences', pp. 249-252
Ornitz EM, ‘Neurophysiologic Studies of Infantile Autism’, Handbook of Autism and Pervasive Developmental Disorders, John Wiley & Sons, Inc., 1987, 148-165
Otsuka H, 'Brain Metabolites in the Hippocampus-amygdala Region and Cerebellum in Autism: an 1H-MR Spectroscopy Study', Neuroradiology 1999 Jul
Page T, Coleman M, ‘Purine metabolism abnormalities in a hyperuricosuric subclass of autism’, Biochim Biophys Acta, 2000 Mar 17;1500(3):291-296
Page T, Yu A, Fontanesi J, Nyhan WL, ‘Developmental disorder associated with increased cellular nucleotidase activity’, Proc. Natl. Acad. Sci. USA, Vol. 94, October 1997, 11601-11606
Paul R, ‘Natural History’, Handbook of Autism and Pervasive Developmental Disorders, John Wiley & Sons, Inc., 1987, 121-132
Pedersen MB, Hansen JC, Mulvad G, Pedersen HS, Gregersen M, Danscher G, ‘Mercury accumulations in brains from populations exposed to high and low dietary levels of methyl mercury.  Concentration, chemical form and distribution of mercury in brain samples from autopsies’, Int J Circumpolar Health 1999 Apr;58(2): 96-107
Pediatrics 1999; 104:570-574, 'Thimerosal in vaccines: an interim report to clinicians', Committee on Infectious Disease and Committee on Environmental Health
Pendergrass JC, Haley BE, Vimy MJ, Winfield SA, Lorscheider FL, ‘Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain’, Neurotoxicology 1997;18(2):315-324
Perry E, Lee M, Court J, Perry R, 'Cholinergic Activities in Autism: Nicotinic and Muscarinic Receptor Abnormalities in the Cerebral Cortex' , presentation to Cure Autism Now, 2000
Pfab R, Muckter H, Roider G, Zilker T, ‘Clinical course of severe poisoning with thiomersal’, Clinical Toxicology 1996;34(4):453-460
Pierce PE, Jon F. Thompson, MPH William H. Likosky, MD; Laurance N. Nickey, MD; William F. Barhtel; and Alan R. Hinman, MD, MPH, ‘Alkyl Mercury Poisoning in Humans’, JAMA 1972 Vol 220, No11 1439-1442
Piikivi L, Hanninen H, Martelin T, et al, ‘Psychological performance and long-term exposure to mercury vapors’, Scand. J. Work Environ. Health, 1984, 10:35-41
Piikivi L, Tolonen U, ‘EEG findings in chlor-alkaliworkers subject to low long term exposure to mercury vapor’, Br. J. Ind. Med., 1989, 46(6):370-375
Pirker C, Möslinger T, Wantke F, Götz, Jarisch R, ‘Ethylmercuric chloride: the responsible agent in thimerosal hypersensitivity’, Contact Dermatitis 1993:29:152-154
Piven J, Berthier M, Starkstein S, Nehme E, Pearlson G, Folstein S, ‘Magnetic resonance imaging evidence for a defect of cerebral cortical development in autism’, American Journal of Psychiatry, June 1990, 147:6, pp. 734-739
Piven J, Palmer P, ‘Psychiatric disorder and the broad autism phenotype: evidence from a family study of multiple-incidence autism families’, American Journal of Psychiatry, April 1999, Vol. 156, No. 4, pp. 557-563
Pless R, 'Summary of the Workshop on Thimerosal in Vaccines', Report from the National Immunization Program, CDC, 1999
Plioplys A, 'Autism: Biomedical Perspectives', Presentation for the Autism Society of America meeting, July 1989
Plioplys AV, Greaves A, Kazemi K, Silverman E, ‘Immunoglobin reactivity in autism and Rett’s syndrome’, Developmental Brain Dysfunction, 1994, 7:12-16
Plioplys AV, Greaves A, Kazemi K, Silverman E, ‘Lymphocyte function in autism and Rett Syndrome’, Neuropsychobiology 1994;29(1) :12-6
Plioplys AV, Hemmens SE, Regan CM, 'Expression of a neural cell adhesion molecule serum fragment is depressed in autism', J Neuropsychiatry Clin Neurosci, 1990 Fall;2(4):413-7
Plotkin S, Orenstein W, Vaccines 1999
Prechtl HFR, 'Neurological Findings in Newborn Infants after Pre- and Paranatal complications', Jonxis et al editors:Aspects of Prematurity and Dysmaturity: a Nutrica symposium, Leiden:Stenfert Kroesse, 1968
Prizant BM, ‘Brief Report: Communication, Language, Social, and Emotional Development’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 173-178
Purine Research Society, 'What We Learn About Metabolic Disease Will Benefit Each and Every One of Us', Purine Research Society Website
Puschel G, Mentlein R, Heymann E, 'Isolation and characterization of dipeptidyl peptidase IV from human placenta', Eur J Biochem 1982 Aug;126(2):359-65
Rajanna B and Hobson M, ‘Influence of mercury on uptake of [3H]dopamine and [3H]norepinephrine by rat brain synaptosomes’, Toxicology Letters 1985 Sep 27(1-3):7-14
Rajanna B, Hobson M, Harris l, Ware L, Chetty CS, ‘Effects of cadmium and mercury on Na(+)-K+, ATPase and uptake of 3H-dopamine in rat brain synaptosomes’, Arch Int Physiol Biochim 1990 Oct;98(5):291-296
Rice D, 'Lack of Effect of Methylmercury Exposure from Birth to Adulthood on Information Processing Speed in the Monkey', September 1997,
Rice DC, ‘Sensory and cognitive effects of developmental methylmercury exposure in monkeys, and a comparison to effects in rodents’, NeuroToxicol., 1996, 17:139-154
Rice DC, Gilbert SG, ‘Early chronic low-level methylmercury poisoning in monkeys impairs spatial vision’ Science 1982 May 14;216(4547):759-761
Richdale AL, 'Sleep problems in autism: prevalence, cause, and intervention', Developmental Medicine and Child Neurology, 1999 Jan 41(1):60-6
Rimland B, ‘Recovery from autism is possible’, cited in Autism Research Review International, 1994, Vol. 8, No. 2, p. 3
Rimland B, Baker SM, ‘Brief Report: Alternative Approaches to the Development of Effective Treatments for Autism’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 237-241
Ritvo ER, Freeman BJ, Scheibel AB, Duong T, Robinson H, Guthrie D, Ritvo A, 'Lower Purkinje cell counts in the cerebella of four autistic subjects: intitial findings of the UCLA-NSAC Autopsy Research Report', American Journal of Psychiatry, 1986;143:862-866
Ritvo ER, Freeman BJ, Creel D, Crandall AS, Pingree C, Barr R, Realmuto G, ‘Retinal Pathology in Autistic Children – A Possible Biological Marker for Subtype?’ (letter), Journal of the American Academy of Child Psychiatry, January 1986, 25:137
Rodier PM, Ingram JL, Tisdale B, Croog VJ, ‘Linking etiologies in humans and animal models: studies of autism’, Reproductive Toxicology, 1997, Vol. 11, Nos. 2/3, pp. 417-422
Rodier, P.M., M. Aschner and P. R. Sager. 1984. Mitotic arrest in the developing CNS after prenatal exposure to methyl mercury. Neurobehav. Toxical. Teratol. 6:379-385.
Rogers SJ, ‘Brief Report: Early Intervention in Autism’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 243-246
Rogers T, Kalaydjieva, Hallmayer et al, 'Exclusion of Linkage to the HLA Region in Ninety Multiplex Sibships with Autism', Journal of Autism and Developmental Disorders, 1999 Jun;29(3):195-202
Rohyans J, Walson PD, Wood GA, MacDonald WA, ‘Mercury toxicity following merthiolate ear irrigations’, The Journal of Pediatrics, 1984 Feb:311-313
Romani L, ‘Immunity to Candida albicans: Th1, TH2 cells and beyond’, Curr Opin Microbiol 1999 Aug;2(4): 363-367
Rosenhall U, Johansson E, Gillberg C, ‘Oculomotor findings in autistic children’, Journal of Laryngology and Otology, May 1988, Vol. 102, pp. 435-439
Rosenhall U, Nordin V, Sandstrom M, Ahlsen G, Gillberg C, 'Autism and Hearing Loss', Journal of Autism and Developmental Disorders, Oct 1999 29(5) 349-358
Ross W. Donald, Gechman A, Sholiton M, Paul H, 'Alertness to Neuropsychiatric Manifestations', Comprehensive Psychiatry, Vol. 18, No. 6, pp. 595-598
Rossi AD, Ahlbom E, Ogren So, Nicotera P, Ceccatelli S, ‘Prenatal exposure to methylmercury alters locomotor activity of male but not female rats’, Exp Brain Res 1997 Dec;117(3):428-436
Roux S, Adrien J-L, Bruneau N, Malvy J, Barthelemy C, 'Behavior Profiles within a population of 145 children with autism using the Behaviour Summarized Evaluation scale: influence of developmental age', Autism, 1998 (Dec) 2(4) 235-266
Rumsey J, ‘Conceptual problem-solving in highly verbal, nonretarded autistic men’, Journal of Autism and Dev. Disorders, 1985, Vol. 15, No. 1, pp. 23-36
Rumsey JM, Hamburger SD, ‘Neuropsychological findings in high-functioning men with infantile autism, residual state’, Journal of Clinical and Experimental Neuropsychology, 1988, Vol. 10, No. 2, pp. 201-221
Russell J, Jarrold C, Hood B, ‘Two Intact Executive Capacities in Children with Autism: Implications for the Core Executive Dysfunctions in the Disorder’, Journal of Autism and Developmental Disorders, 1999, Vol. 29, No. 2, 103-112
Rutter M, 'Autism research: prospects and priorities', Journal of Autism and Developmental Disorders 1996 Apr;26(2):257-75
Rutter M, ‘The development of infantile autism’, Psychological Medicine 1974 4:147-163
Ryu YH, Lee JD, Yoon PH, Kim DI, Lee HB, Shin YJ, ‘Perfusion impairments in infantile autism on technetium-99m ethyl cysteinate dimer brain single-photon emission tomography: comparison with findings on magnetic resonance imaging’, Eur J Nucl Med 1999 Mar;26(3):253-259
Sager. P.R., Aschner, M., and Rodier, P.M. 'Persistent differential alteration in developing cerebellar cortex of male and female mice after methylmercury exposure', Dev. Brain Res. 12: 1-11 (1984)
Sarafian TA, Bredesen DE, Verity MA, ‘Cellular resistance to methylmercury’, Neurotoxicology, 1996 Spring Abstract, 17(1):27-36
Sayers LG, Brown GR, Michell RH, Michelangeli F, ‘The effects of thimerosal on calcium uptake and inositol 1,4,5-triosphate-induced calcium release in cerebellar microsomes’, Biochem J 1993 Feb 1;289 (Pt 3):883-887
Schuler AL, ‘Thinking in Autism: Differences in Learning and Development’, Teaching Children with Autism, Kathleen Ann Quill, ed., 1995, 11-32
Sears LL, 'An MRI Study of the Basal Ganglia in Autism', Prog Neuropsychopharmacol Biol Psychiatry, 1999 May
Shafer TJ, Atchison WD, ‘Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies’, Neurotoxicology 1991 Fall;12(3):473-492
Shattock P, Savery D, Autism as a Metabolic Disorder, Autism Research Unit, University of Sunderland, Sunderland, UK, 1997
Shenker BJ, Datar S, Mansfield K, Shapiro IM, ‘Induction of apoptosis in human T-cells by organomercuric compounds: a flow dytometric analysis’, Toxicol Appl Pharmacol, April 1997, 143(2): 397-406
Shenker BJ, Guo TL, Shapiro IM, ‘Low-level methylmercury exposure causes human T-cells to undergo apoptosis: evidence of mitochondrial dysfunction’, Environmental Research, 1998 May; Section A 77(2):149-159
Shenker, B.J., Berthold, P., DeBolt, K., Rooney, C., Vitale, L.A., and Shapiro, I.M. (1992).  'Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes.  II.  Alterations in cell viability',  Immunopharm.  Immunotox. 14, 555-577.
Shenker, B.J., Berthold, P., Decker, S., Mayro, J.S., Rooney, C., Vitale, L.A., and Shapiro, I.M. (1993).  'Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes. III. Alterations in B-cell function and viability',  Immunopharm.  Immunotox. 15, 87-112. 
Siegel BV, Nuechterlein KH, Abel L, Wu JC, Buchsbaum MS, ‘Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls’, Schizophrenia Research 1995 Sep 17(1):85-94
Sigman M, Ungerer JA, Mundy P, Sherman T, ‘Cognition in Autistic Children’, Handbook of Autism and Pervasive Developmental Disorders, John Wiley & Sons, Inc., 1987, 103-130
Singh VK, 'Plasma increase of Interleuken-12 and Interferon-gamma. Pathological significance in autism', J Neuroimmunology, 1996 May;66(1-2):143-5
Singh VK, Warren RP, Odell D, 'Immune response to brain myelin in autistic children', July 1992
Singh V, Warren R, Odell J, Warren W, Cole P, 'Antibodies to myelin basic protein in children with autistic behavior', Brain, Behavior and Immunity, 1993 Mar;7(1):97-103
Singh VK et al, Biological Psychiatry 1997 41: 753-755
Singh VK, Fudenberg HH, Emerson D, Coleman M, ‘Immunodiagnosis and immunotheraphy in autistic children’, Annals of the New York Academy of Science, 540, 1988, 602-604
Singh VK, Journal of Neuroimmunology 1996 66: 143-145
Singh,VK et al, Brain, Behavior and Immunity 1993 7: 97-103 - http://www.whale.to/vaccines/binstock5.html
Smalley SL, Collins F, ‘Brief Report: Genetic, Prenatal, and Immunologic Factors’, Journal of Autism and Developmental Disorders, 1996, Vol. 26, No. 2, 195-198
Smith D., 'Mental Effects of Mercury Poisoning',  Presentation before the Section on Family Practice, Southern Medical Association, 71st Annual Scientific Assembly, November 6-9, 1977
Snyder RD.  ‘The involuntary movements of chronic mercury poisoning’, Archives of  Neurology 1972;26:379-3381
Sperry VW, 'Family and personal section: From the inside out - a view of the world as seen by one with Asperger syndrome', Autism, 1998 Marc;2(1):81-86
Sternberg RJ, 'A Unified Theoretical Perspective on Autism', Handbook of Autism and Pervasive Developmental Disorders, Cohen DJ, Donnellan AM, Paul R, eds, 1987 by John Wiley & Sons, p.690-696
Stevenson RE, Schroer RJ, Skinner C, Fender D, Simensen RJ, 'Autism and macrocephaly', Lancet, 1997, 349:1744-1745
Stores G, Wiggs L, 'Abnormal sleeping patterns associated with autism: a brief review of research findings, assessment methods and treatment strategies', Autism, 1998 Jun;2(2):157-170
Stubbs EG, ‘Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination’, Journal of Autism and Childhood Schizophrenia, 6, 269-274, 1976
Sutton KG, McRory JE, Guthrie H, Murphy TH, Snutch TP, 'P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A', Nature 1999 Oct 21;401(6755):800-4
Szasz A, Barna B, Szupera Z, De Vixxcher G, Galbacx Z, Kirsch-Volders M, Szente M, ‘Chronic low-dose maternal exposure to methylmercury enhances epileptogenicity in developing rats’, Int J. Devl Neurosci, 1999, 17.7.733-742
Szatmari P, Bartolucci G, Bremner R, Bond S, Rich S, ‘A follow-up study of high-functioning autistic children’, Journal of Autism and Developmental Disorders, June 1989, Vol. 19, No. 2, pp. 213-225
Tan XX, Tang C, Castoldi AF, Manzo L, Costa LG, ‘Effects of inorganic and organic mercury on  intracellular calcium levels in rat T lymphocytes’, Journal of Toxicology & Environmental Health, 1993 Feb;38(2):159-170
Teitelbaum P, Teitelbaum O, Nye J, Fryman J, Maurer RG, ‘Movement analysis in infancy may be useful for early diagnosis of autism’, Proc. Natl. Acad. Sci. USA, Vol. 95, November 1998, 13982-13987
The MAAP, Volume IV, 1996; Volume VI, 1996; Volume III, 1999; Volume IV, 1997; Volume II, 1997; Volume I, 1997; Volume II, 1998; Volume IV, 1998, MAAP Services, Inc., PO Box 524, Crown Point, IN 46308
Thrower EC, Duclohier H, Lea EJ, Molle G, Dawson AP, ‘The inositol 1,4,5-trisphosphate-gated Ca2+ channel: effect of the protein thiol reagent thimerosal in channel activity’, Biochem J 1996 Aug 15;318 (Pt 1): 61-66
Tokuomi H. Uchino M. Imamura S. Yamanaga H. Nakanishi R. Ideta T, ‘Minamata disease (organic mercury poisoning):  Neuroradiologic and electrophysiologic studies’,  Neurology 1982;32:1369-1375)
Tonge BJ, Brereton AV, Gray KM, Einfeld SL, 'Behavioural and emotional disturbance in high-functioning autism and Asperger's syndrome', Autism, 1999 Jun;3(2):117-130
Trottier G, Srivastava L, Walker CD, ‘Etiology of Infantile Autism: a review of recent advances in genetic & neurobiological research’, Journal of Psychiatry & Neuroscience, 1999 March 24(2):103-115
Tsai LY, 'Brief Report: Comorbid Psychiatric Dosorders of Autistic Disorder', Journal of Autism and Developmental Disorders, April 1996 26(2)159-164
Tuunanen J, Halonen T, Pitkanen A, ‘Decrease in somatostatin-immunoreactive neurons in the rat amygdaloid complex in a kindling model of temporal lobe epilepsy’, Eiplepsy Res, 1997, 26.315-327
Tuunanen J, Halonen T, Pitkanen A, ‘Status epilepticus causes selective regional damage and loss of GABAergic neurons in the rat amygdaloid complex,’ Eur J Neurosci, 1996, 8:2711-2725
Tuunanen J, Lukasiak K, Halonen T, Pitkanen A, ‘Status epilepticus-induced neuronal damage in the rat amygdaloid complex: distribution, time-course and mechanisms’, Neurosci, 1999, 94.2.473-495
Uchida T, Naito S, Kato H, Hatano I, Harashima A, Terada Y, Ohkawa T, Chino F, & Eto K, ‘Thimerosal induces toxic reaction in non-sensitized animals’, International Archives of Allergy & Immunology, 1994 104(3):296-301
Vahter M, Mottet NK, Friberg L, Lind B, Shen DD, Burbacher T, ‘Speciation of mercury in the primate blood and brain following long-term exposure to methyl mercury’, Toxicol Appl Pharmacol, 1994 Feb;124(2):221-229
Volterra A, Trotti D, Cassutti P, Tromba C, Salvaggio A, Melcangi RC, Racagni G, ‘High sensitivity of glutamate uptake to extracellular free arachidonic acid levels in rat cortical synaptosomes and astrocytes’, Journal of Neurochemistry 1992 Aug 59(2):600-606 - http://www.autism.com/triggers/vaccine/mercury.htm
Von Burg R, Rustam H, ‘Conduction Velocities in Methylmercury Poisoned Patients’, Bulletin of Environmental Contamination & Toxicology, 1974, 12(1):81-85
Von Burg R, Rustam H, ‘Electrophysiological Investigations of Methylmercury Intoxication in Humans. Evaluation of Peripheral Nerve by Conduction Velocity and Electromyography’, Electroencephalography and Clinical Neurophysiology, 1974, 37:381-392
Vostanis P, Smith B, Corbett J, Sungum-Paliwal R, Edwards A, Gingell K, Golding R, Moore A, Williams J, ‘Parental concerns of early development in children with autism and related disorders’, Autism, September 1998, Vol. 2, No. 3, 229-242
Vroom FQ, Greer M, 'Mercury Vapour Intoxication', Brain (1972) 95, 305-318
Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Chillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA, ‘Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children’, The LANCET, February 28, 1998, Vol. 351, 637-641
Warfvinge K, Hua J, Logdberg B, 'Mercury distribution in cortical areas and fiber systems of the neonatal and maternal cerebrum after exposure of pregnant squirrel monkeys to mercury vapor', Environ Res 1994 Nov;67(2):196-208
Warkany J, Hubbard DH, 'Acrodynia and Mercury', J Pediatrics 1953 42;365-386
Warren RP, Margaretten NC, Foster A, ‘Reduced Natural Killer Cell Activity in Autism’, Journal of the American Academy of Child and Adolescent Psychiatry, 1987, Vol. 26, No. 3, pp. 333-335
Warren RP, Margaretten NC, Pace NC, Foster A, ‘Immune Abnormalities in Patients with Autism’, Journal of Autism and Developmental Disorders, 1986, Vol. 16, No. 2, pp. 189-197
Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR, ‘Strong association of the third hypervariable region of HLA-DRß1 with autism’, Journal of Neuroimmunology 67 (1996) 97-102
Warren RP, Yonk LJ, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK, 'Deficiency of Suppressor-inducer (CD4+CD45RA+) T Cells in Autism', Immunological Investigations, 1990 Jun 19(3):245-251
Watanabe C, Kasanuma Y, Dejima Y, Satoh H, ‘The effect of prenatal nethylmercury exposure on the GSH level and lipid peroxidation in the fetal brain and placenta of mice’, Tohoku J Exp Med 1999 Feb;187(2):121-126
Watzl B, Abrahamse SL, Treptow-van Lishaut S, Neudecker C, Hansch GM, Rechkemmer G, Pool-Zobel BL, 'Enhancement of ovalbumin-induced antibody production and mucosal mast cell response by mercury', Food Chem Toxicol 1999 Jun;37(6):627-37
Wecker L, Miller SB, Cochran SR, Dugger DL, Johnson WD, ‘Trace Element Concentrations in Hair From Autistic Children’, J. ment Defic. Res. (1985) 29, 15-22
Weitzman A, Weisman R, Szekely GA, Wijsenbeek H, Livni E, 'Abnormal immune response to brain tissue antigen in the syndrome of autism', Am J Psychiatry 1982 Nov;139(11):1462-5
Whiteley P, Rogers J, Shattock P, ‘Clinical features associated with autism: observations of symptoms outside the diagnostic boundaries of autistic spectrum disorders’, Autism, December 1998, Vol. 2, No. 4, 415-422
Wild GC, Benzel EC, Essentials of Neurochemistry, Jones and Bartlett Publishers, Inc., 1994
Williams D, Autism - An Inside-Out Approach, 1996, Jessica Kingsley Publishers Ltd, London
Wing L, Attwood A, ‘Syndromes of Autism and Atypical Development’, Handbook of Autism and Pervasive Developmental Disorders, John Wiley & Sons, Inc., 1987, 3-19
Wing, Lorna (1996) ‘Autism Spectrum Disorder’, British Medical Journal 312: 327-328
Wu J, Takeo T, Kamimura N, Wada J, Suga S, Hoshina Y, Wakui M, ‘Thimerosal modulates the agonist-specific cytosolic Ca2+ oscillatory patterns in single pancreatic acinar cells of mouse’, FEBS Lett 1996 Jul 22;390(2):149-152
Yamagata T, 'FRAXE mental retardation', Nippon Rinsho 1990 Apr;57(4):955-9
Yard BA, Lorentz CP, Herr D, and Van Der Woude F, ‘Sulfation-dependent down-regulation of interferon-gamma-induced Major Histocompatibility Complex I and II Intercellular Adhesion Molecule-1 expression on tubular and endothelial cells by glycosaminoglycans’, Transplantation Vol.66(9), November 15, 1998, pp. 1244-1250
Yazbak FE, ‘Autism ‘99, a national emergency’, http://www.garynull.com/documents/autism_99.htm   (Internet publication) 1999
Yeates KO & Mortensen ME, ‘Acute and chronic neuropsychological consequences of mercury vapor poisoning in two early adolescents’, Journal of Clinical Exp Neuropsychology, 1994 16(2):209-222
Yip RK, Riley DA, ‘Effects of methylmercury on the motor and sensory and innervation of the rat extensor digitorum longus muscle’, Environ Res 1987 Jun;43(1):85-96.
Yuan Y, and Atchison WD, ‘Comparative effects of methylmercury on parallel-fiber and climbing fiber responses of rat cerebellar slices’, Journal of Pharmacology and Experimental Therapy 1999 Mar;288(3):1015-1025.
Zimmerman A, Brashear R, Frye V, Potter N, 'Anticerebellar Antibodies in Autism', pp. 275-276
Zimmerman A, Frye VH, Potter NT, ‘Immunological aspects of autism’, International Journal of Pediatrics, 8, 1993, 199-204
Zimmerman AW, Gonfardin B, Myers SM, Neuropharmacological therapy in autism, Autism: Clinical and Research Issues, ed. Pasquale Accardo, et al., Timonium, MD: York Press, 1996


Altra Bibliografia - References
1. Professor Margot Prior, a presentation at the Cato Conference Centre, May 17th, 1999. First printed in Austism News September 1999
2. Changes in Population of Persons with Autism and Pervasive Developmental Disorders in California's Developmental Services System: 1987-1998, a Report of the Legislature, March 1, 1999.
3. Changes in Population of Persons with Autism and Pervasive Developmental Disorders in California's Developmental Services System: 1987-1998, a Report of the Legislature, March 1, 1999.
4. Singh V, Yang V. Serological association of measles virus and human herpes virus-6 with brain autoantibodies in autism. Clinical Immunology and Immunopathology 1998;880):105-108.
5. Massimo Montinari, et aL, Department of Pediatric Surgery, University of Bari, Italy, presented May 9, 1996
http://www.healthy.net/library/articles/coulter/biochem.htm  
6. Bolte E, "Autism and Clostridium, Tetani: An Hypothesis" [Medical Hypotheses, vol. 51, 1998, pages 133-144.
7. Wakefield A.J, et al. fleal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-641. 17. Kumar S, Miller LK. Effects of serial passage of Autographa California nuclear poly hedrosis virus in cell culture. Virus Research 1987;7:335-349.
8. Wakefield et a] (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.
Lancet 351; 637-641.
9. Martin WJ, et al.
Stealth virus epidemic in Mohave Valley, 1: Initial report of virus isolation. Pathobiology 1997;65(l):351-356.
10. Gupta S, et al. Dysregulate immune system in children with autism, beneficial effects of intravenous globulin on autistic characteristics. J of Autism and Developmental Disorders 1996;26(4):439452.
11. www.autism.com/ari/mercury.html  
12. Gillberg C., Coleman M. The Biology of the Autistic Syndromes, 2nd edn. London: MacKeith Press, 1992.
13. Alm JS, et al. Atopy in children of families with an anthroposophic lifestyle. Lancet 1999;353:1485-1488.
14. "Elevated Serotonin Levels in Autism: Association With the Major Histocompatibility Complex." Neuropsychobiology, vol. 34, number 2, 1996, pp. 72-5
15. O Reilly B. A., Waring, R. Enzyme and sulphur oxidation deficiencies in autistic children with known food/chemical intolerances. Journal of Orthomolecular Medicine 1993; 4: 198-200.
16. Markovich D., Knight D., Renal Na-Si cotransporter NaSi-1 is inhibited by heavy metals. American Journal of Renal Physiology 1998; 274(2): Z83-289.
17. Horvath, Stefanatos, Sokolski, Wachtel, Nabors & Tildon, 1998
18. Dr Kalle Reichelt, NORWAY http://osiris.sunderland.ac.uk/autism/sec.htm
19. VK Singh , Lin SX , Newell E, Nelson C. Anomalia negli anticorpi morbillo-parotite-rosolia e autoimmunità del sistema nervoso centrale nei bambini autistici, J Biomed Sci. lug 2002-ago.
20.
VK Singh, Lin SX, Yang VC. Associazione sierologica del virus del morbillo e dell’herpes virus umano-6 (HHV-6) con gli autoanticorpi cerebrali nell'autismo,
21. Clin Immunol Immunopathol, Ottobre 1998Richmand BJ. Ipotesi: vaccini coniugati possono predisporre i bambini al disturbo dello spettro autistico, Med Hypotheses. Dic. 2011

Continua da e in:
  Autismo Refenze 2 + Autismo Refenze - 3 + Amish senza autismo perche' NON vaccinano
+ Autismo + Bibliografia per autismo dai Vaccini
e QUI
http://healthimpactnews.com/2014/the-vaccine-autism-cover-up-how-one-doctors-career-was-destroyed-for-telling-the-truth/
 

E questa è solo una piccolissima parte della Bibliografia esistente sui Danni da vaccino !
VACCINS DAMAGES
+
Bibliografia Danni dei vaccini  +  Bibliografia danni 2  +  Bibliografia  +  Bibliografia 2  +  Bibliografia 3 Bibliografia 4 + Sostanze eterologhe nei vaccini e reazioni  +  INGREDIENTI TOSSICI anche OCCULTI, di alcuni VACCINI analizzati + Contenuto nel vaccini Trivalenti (difpertal)  +  Come si producono i Vaccini

HOME

BACK